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Executive summary 
Background 
More than 7 000 drug-related deaths (DRDs) are reported every year in Europe, which is 
equivalent to a mortality of circa 18 deaths per million population aged 15-64 years. 
However, there is considerable variation in the extent of DRDs in European countries: the 
rates reported in many of the northernmost European countries exceed 40 per million 
population, whereas in many southern European countries there are fewer than 10 DRDs 
per million per annum. There are also variations in the patterns of drug use, the drug 
markets and the national responses. The sensitivity of DRD recording systems may also 
vary between countries. The sensitivity of these recording systems may also vary over time, 
confounding temporal comparisons. 
In this report, we summarise the findings of a project to examine the triggers and dynamics 
of DRDs in the seven northern European countries with the highest DRD rates per general 
population: Denmark, Estonia, Finland, Ireland, Norway, Sweden and Scotland (United 
Kingdom) during the 2004-2014 period. The project considered whether or not between-
country variation in DRDs, and trends therein, might be explained in terms of: 
• differences in (and changes to) mechanisms for recording DRDs; 
• differences (and trends) in the number of drug users at risk of DRD; 
• differences (and trends) in the level of DRD risk among those who are at risk. 
The analysis is based on a series of country profiles (see Appendices A.1-7 for country 
profile summaries). These profiles were developed in consultation with national experts from 
the participating countries and summarise the available aggregate-level data pertinent to 
drug-related mortality. Many of these data derive from European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) standard indicators, principally estimates of the prevalence 
of high-risk drug use; data on treatment seekers, demand, availability and coverage; the 
prevalence of drug-related infectious diseases; and the availability of primary harm-reduction 
measures. Structured interviews with national data providers and stakeholders were 
conducted, followed by a workshop involving national experts and the EMCDDA. 
Key findings 
In all seven countries, opioids were implicated in the bulk (circa 80-90 %) of DRDs. 
Therefore, opioid-related deaths were the project’s primary focus. 
In all six of the countries for which trend data were available, the number of recorded DRDs 
involving opioids increased during the early part of the time series (up to 2008/2009). Most of 
these six countries exhibited an interruption to this increasing trend during 2010, the period 
of the European ‘heroin drought’. It is conceivable that reduced availability of heroin during 
this drought contributed to a reduction in both the number of individuals at (and/or occasions 
of) immediate risk and the level of risk involved. Thereafter (up to 2014), in only one of the 
six countries (Sweden) was there a clear and sustained increase in recorded DRDs, 
although more recent data (not covered here) indicate subsequent increases in Scotland and 
Ireland. 
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Many countries used more than one information source to inform their recording of DRDs, 
although not all cross-checked data from multiple sources (which is recommended by the 
EMCDDA European DRD protocol). It was beyond the scope of the project to undertake a 
detailed examination of recording mechanisms and coding practices in all seven countries, 
but it appeared that their case capture was likely to be reasonably complete. This is on the 
basis that autopsy rates for overdose cases were high and that post-mortem toxicology data 
were available and recorded. This apparently high level of case capture may contribute to 
the perception that these northern countries have higher levels of DRDs than countries in 
which data collection is less sensitive and therefore less complete. 
Most countries indicated that their recording and reporting mechanisms were reasonably 
consistent over the period considered. Nonetheless, in Sweden, where a parallel project 
undertook a detailed examination of case-level mortality data and the mechanisms used to 
record and code DRDs, even quite subtle changes were found to have improved the 
sensitivity of the national recording system. The cumulative effect of these changes explains, 
in part, the substantial increase in DRDs that Sweden recorded between 2004 and 2014. 
As well as considering the validity of the recorded number of DRDs (the numerator), the 
analysis explored the feasibility of using an alternative, more informative, denominator to 
compare national DRD rates. These rates are often presented on the basis of the number of 
deaths per capita of the general population, which is helpful in illustrating the population 
burden of DRDs. However, the general population DRD rate is a function of both (1) the 
prevalence of individuals at risk of DRD and (2) the level of risk to which they are exposed. 
Across Europe, estimates indicate as much as a 30-fold difference in prevalence rates for 
the main at-risk group (high-risk opioid users (HROUs), on the basis that these account for 
the bulk of DRDs). Thus, comparison of DRD population rates is only marginally informative, 
because it conflates (known, even if imprecisely) variation in prevalence with (uncertain) 
variation in risk. Comparison of DRD rates per HROU, where this is available, is potentially 
more informative, because it might highlight geographical or temporal differences in risk (1) 
and factors that may mitigate this. Available prevalence estimates for the seven countries 
were not, strictly, a suitable denominator to support this analysis (because of imprecision, 
and differences in case definition, estimation methodology, etc.) and suitable prevalence 
trend estimates were not available. However, the number of DRDs in each country was 
roughly in proportion to a ‘best approximation’ of the size of its at-risk population. That is, for 
most countries, DRD rates among the at-risk population were within a broadly similar range. 
This illustrates that differences in prevalence are likely to be a major contributor to 
differences in DRD population rates; previous comparisons, limited by HROU estimate 
availability (in 2016, only 12 out of 30 countries had a recent estimate (within the previous 
three years)), have tended not to take proper account of this. This observation may also lend 
a degree of support to the validity of the available prevalence estimates, albeit more analysis 
would be required to confirm this. 
There was indirect, albeit tentative, evidence that the seven countries differed with regard to 
factors that are likely to influence the level of DRD risk among their at-risk populations. 
Available indicators (from treatment and toxicology data) indicate heterogeneity between 
(1) Cohort studies provide the optimal approach to assessing risk, but are scarce and often not comparable. This is 
discussed further in the report. 
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countries in the degree of behavioural risk involved in opioid use, especially with regard to 
the type of opioids typically consumed (heroin vs. fentanyl vs. other opioids), patterns of 
adjunctive (polydrug) use, and the prevalence of injecting (which was markedly higher than 
the European  ‘average’ in some countries). There were also differences in potential 
demographic risk/vulnerability, whereby some countries had an older at-risk population 
(which is relevant because DRD risk increases with age). In addition, there was some 
indication of differences in contextual factors that are likely to be associated with the level of 
risk, such as countries’ treatment coverage or the prevalence of blood-borne virus (BBV) 
infection. It is notable that Estonia, for which comparison of the number of DRDs with the 
number of users at risk indicated a potentially greater than average risk, also exhibited a 
range of contributory factors (high rates of fentanyl use, high rates of injecting and a high 
prevalence of BBV infection) associated with elevated risk. 
 
Limitations 
A limitation of this report is that it does not consider, in detail, the seven countries’ DRD 
coding and recording practices, or the data flow between their different mortality registers. 
These aspects are covered in a parallel project, commissioned by the EMCDDA in 2016, 
that considers these factors for all 30 countries and for a range of southern European 
countries in particular for some aspects of the project (England, 2017a, 2017b, 2017c). 
Additional exploration of market data (the availability and purity of the opioids in common 
use) would have added to the ability to explore the level of risk, but this was not possible 
because of the scarcity of supporting data. Also, data to support analysis of other key factors 
that affect DRD risk, such as the extent of recent imprisonment or psychiatric comorbidity 
and the quality or duration of treatment, were not analysed. 
 
Recommendations 
Clearly, countries should continue to endeavour to produce and use robust DRD data, 
including information about toxicology that is indispensable for the basic descriptive 
epidemiology of DRDs. Several recommendations emerged from the project, based on 
analysis and the advice of the national experts, designed to help countries place their DRD 
data within the proper context, in order to facilitate temporal and geographical comparison 
and better inform knowledge about the epidemiology of DRDs for policymaking. Three key 
recommendations are summarised below: 
1. The number of deaths per capita of the general population is helpful for illustrating 
the population burden of DRDs, but general population rates for DRDs should not be 
used as a basis for the geographical or temporal comparison of DRD risk. 
2. Countries should produce more specific estimates of the prevalence of high-risk 
opioid use, to provide a denominator to support comparisons of opioid-related DRD 
rates (and thereby risks). 
3. Preferably, to assess DRD risk, countries should undertake (or regularly update) 
mortality cohort studies (notwithstanding the difficulty of recruiting representative 
cohorts of sufficient size and ensuring comparability with other studies). 
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Cross-indicator analysis, such as that undertaken here, should be encouraged and the 
findings communicated to policymakers. To support this, it is suggested that EMCDDA 
indicator data (e.g. treatment demand data) that are more specific to the main at-risk 
population (i.e. HROUs) are analysed against DRD data. 
 
Conclusions 
The population burden of DRDs is high; this is evident especially in northern Europe. As 
illustrated here, simple comparisons of the numbers of DRDs and the associated population 
rates are unlikely to yield meaningful inferences about the causes of such high rates in 
northern Europe, because much of the variation in DRD rates can be explained in terms of 
variation in the prevalence of users at risk. 
A broad range of factors may contribute to differences (or changes) in the level of DRD risk 
within the at-risk population. However, (1) there may be complex interactions between 
drivers; and (2) upwards and downwards drivers will operate simultaneously. Thus, it is 
unlikely that a single explanatory factor exists or could be identified. 
DRDs occur within a highly complex and dynamic context. Policymakers should understand 
that simple hypotheses about the impact, if any, of the responses to DRDs that are (or are 
not) provided should be avoided. In the absence of properly controlled studies, even if the 
number of DRDs is increasing, it should not be assumed that interventions put in place to 
reduce risk are not effective. 
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1.0: Background 
This report summarises the findings of a project to examine drug-related deaths (DRDs) in 
seven selected European countries: Denmark, Estonia, Finland, Ireland, Norway, Scotland 
and Sweden and. These countries have been selected by the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) on the basis that: 
• they may have high, and in some cases increasing, numbers of recorded DRDs; 
• their general population rate for DRDs is above the EU average (EMCDDA, 2016a). 
As discussed later in this report, and depending on the objective of the comparison, general 
population rates for DRDs may not be the preferred measure for the purposes of comparison 
between countries. 
The project was designed to develop an understanding of the triggers and dynamics of drug-
related mortality in these countries by considering the national contexts of these deaths; 
comparing the different national situations; and investigating the possible impact of 
methodological changes (in these seven countries) in the manner of recording DRDs, if 
these exist. 
The report is based on a series of country profiles (see Appendices 1-7 for profile 
summaries), which have been developed in consultation with national experts from the 
participating countries and which summarise the available indicator data pertinent to drug-
related mortality, much of which derives from EMCDDA standard indicators. These country 
profiles draw together relevant information to consider whether or not, and if so why, DRD 
rates in the selected countries are high or increasing; the profile of drug use in each country, 
including wider contextual factors; how trends in drug-related mortality have evolved and the 
drivers for the changes observed; the coverage of autopsies/toxicological examination in 
each country; and coding and data collection practices in each country. The information 
presented is based upon the following: 
• a review of the quantitative data reported though Fonte to the EMCDDA; 
• a review of national reports/workbooks/country profiles; 
• a review of the pertinent literature; 
• structured interviews with the focal point/national experts from each of the seven 
countries; 
• the collation of the data reported by the countries  to the EMCDDA on harm 
reduction, treatment, infections, prices and purity. 
A parallel project investigated the mechanisms used by 19 of 30 (the 28 EU Member States 
plus Norway and Turkey) European countries to record DRDs and the comparability thereof, 
including detailed examinations of coding practices and the use of specific ICD-10 (10th 
revision of the International Statistical Classification of Diseases and Related Health 
Problems) codes (England, 2016; England, 2017a; 2017b; 2017c; Giraudon et al., 2016a). 
The work of this parallel project highlights examples of good practice and the issues related 
to the only partial national coverage of DRD recording in many countries. 
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Box 1 describes the sources (general mortality registers (GMRs) and special registers 
(SRs)) from which Member States obtain information regarding DRDs. Six of the seven 
countries considered here provided data derived from a GMR (Selection B), while Ireland 
provided data based on an SR (Selection D). The DRD figures reproduced here are based 
on these sources, but many countries maintain additional registers to meet their particular 
national needs. 
 
As shown in Chapter 4, in all of the countries considered here, opioids are implicated in the 
bulk (circa 80-90 %) of DRDs. The number of deaths that do not involve opioids is very 
small; thus, small variations in these have a disproportionate effect on the apparent non-
opioid trend and patterns are more difficult to discern. Therefore, the primary focus of the 
project reported here was on attempting to understand the context of opioid-related deaths. 
 
 
  
Box 1: Drug-related deaths, definition 
In its DRD protocol, the EMCDDA defines DRDs (more precisely, drug-induced deaths (DIDs)) as follows: 
‘...people who die directly due to use of illegal substances, although these often occur in combination with 
other substances such as alcohol or psychoactive medicines. These deaths occur generally shortly after the 
consumption of the substance. They are also known as overdoses or poisonings’. 
 
The EMCDDA standard protocol transforms this definition into operative criteria for extracting the relevant 
deaths from both General Mortality Registers (GMR) and Special Registers (SR) (types of death) in a way 
that provides the best possible estimation for the number of cases matching this definition. For the GMR, 
these operative criteria consist of a list of codes from the WHO International Classification of Diseases (ICD) 
10th Edition. For the SR they consist of the classes of deaths that should be extracted (only overdoses out of 
all possible cases recorded in these registries e.g. traffic accidents, violence). 
 
The DRD protocol specifies the following: ‘For GMR, the list of ICD-10 codes is known as “Selection B”. They 
include cases where the underlying cause of death (the condition that initiated the process that lead to the 
death) is: (1) mental and behavioural disorders due to psychoactive substance use (harmful use, 
dependence, and other mental and behavioural disorders (F codes) due to opioids, cannabinoids, cocaine, 
other stimulants, hallucinogens or multiple drug use, or (2) poisonings (X and Y codes) that are accidental, 
intentional or of undetermined intent due to substances under the heading of narcotics (T40-0 to T40-9) or 
psychostimulants (T43.6). For the SR, the EMCDDA operative criteria are known as “Selection D”. Cases are 
selected when the deaths are due to poisoning by accident, suicide, homicide, or undetermined intent by a 
set of illegal drugs of abuse.’ 
 
(EMCDDA, 2010; EMCDDA, 2011a) 
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2.0: Understanding the context of drug-related deaths — 
prevalence and risk 
  
2.1: Drivers of drug-related deaths 
In simple terms, in order to understand the context of DRDs, which is necessary if we are to 
make meaningful comparisons between countries and over time, we must consider two key, 
interacting drivers, which are the primary factors explaining the number (and general 
population rates) (2) of DRDs that occur: 
1. the number of drug users who are at risk of DRD; 
2. the level of risk involved. 
Perhaps the more important of these is the number of individuals in the population who 
engage in drug use that involves a risk of overdose or drug poisoning (hereafter ‘at-risk drug 
users’; see Section 2.2 for further discussion of the groups affected). The second factor is 
the degree of risk that is associated with such drug use (Waal and Gossop, 2014). Put 
simply, the larger the number of individuals who are at risk of DRD and the greater the 
degree of risk involved, the larger the number who will die as a consequence of drug use. 
Countries differ, and there are likely to be changes over time within countries, with respect to 
the number (and prevalence rate) of at-risk drug users within their populations. Countries 
may also differ, and there may be differences over time, with respect to the degree of risk 
associated with such drug use. Differences in risk may be explained in terms of a variety of 
different factors, such as the availability of treatment or specific interventions to reduce risk; 
behavioural risk (e.g. the extent of polydrug/polysubstance use or the extent to which 
injecting is a mode of administration among the at-risk population); demographic risk (e.g. 
the age of the at-risk population); etc. Thus, we should expect to see differences between 
countries and over time in the number and general population rate of DRDs. 
 
2.2: Comparison of DRD risk among at-risk drug users 
The prevalence of at-risk drug users may be a primary driver of differences or, for temporal 
changes, in the extent of drug-related mortality. However, in policy terms it is perhaps 
equally important to understand whether or not there are differences between countries or 
over time in the degree of risk associated with drug use among at-risk drug users. Here, the 
question is not whether there are more DRDs in one country than in another or whether the 
number of DRDs is increasing or decreasing, but whether DRD among at-risk drug users in 
one place or at one time is more or less likely than in another place or at another time. That 
is, are there national or temporal differences in the rate of DRDs among those drug users 
(2) Note that the DRD rates reported in the European Drug Report are calculated on the basis of the 
number of DRDs (among 15- to 64-year olds) divided by the number of persons in the general 
population aged 15-64 years. 
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who are at risk? If these rates differ then we might conclude that this reflects underlying 
differences in the degree of risk involved. 
 
Box 2: Comparison of hypothetical countries 
 
Country A  
100 opioid DRDs per annum 
General population = 1 000 000 persons 
Estimated POU prevalence 5 000 persons 
(POU population rate = 50 per 10 000) 
 
General population DRD rate = 1 per 10 000 
POU DRD rate = 200 per 10 000 
 
 
 
 
 
 
 
 
 
= 
≠ 
Country B 
500 opioid DRDs per annum. 
General population = 5 000 000 persons 
Estimated POU prevalence = 60 000 persons 
(POU population rate = 120 per 10 000) 
 
General population DRD rate = 1 per 10 000 
POU DRD rate = 83 per 10 000 
 
 
Comparison of DRD risk requires both accurate measurement of the number of DRDs that 
occur and knowledge of the size of the drug user population in which these deaths occur. As 
noted earlier, the majority of DRDs in the countries considered here involve opioids and the 
primary focus of this report is on opioid-related deaths. Therefore, putting aside the question 
of differences in the accuracy of recorded DRD figures, the EMCDDA indicator for estimates 
of the prevalence of problem opioid use (POU; see Box 4) (3) would provide the most 
suitable denominator with which to frame national DRD figures. 
It should be noted that, whilst the number of DRDs per capita of the general population is a 
helpful indicator of the population burden that arises from DRDs, it is not an adequate basis 
for comparing risk within the at-risk population, because prevalence rates for at-risk drug 
users differ between countries and over time. For example, available estimates indicate a 
more than 30-fold difference in POU prevalence rates between EU countries (EMCDDA, 
2016b). This variation in prevalence rates may perhaps be exaggerated by differences in 
national definitions or methodologies, but the differences will confound comparisons of risk 
based on general population rates. Box 2 shows an illustrative comparison of two 
(hypothetical) countries; where comparison based on the general population rate for DRDs 
indicates similar rates in each country, but disguises a more than twofold difference in the 
DRD rate for the POU population specifically. Thus, similarities or differences in general 
population rates for DRDs do not, necessarily, signify similarities or differences in POU DRD 
risk. Temporal comparisons will be similarly confounded if POU prevalence rates have 
changed over time. 
 
  
(3) The EMCDDA POU indicator was, in 2013, relabeled as the high-risk opioid use indicator; the estimates 
presented in this report were produced prior to this change. 
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3.0: Country comparisons — mechanisms for recording drug-
related deaths 
 
A key consideration, especially when considering trends over time, is whether or not there 
have been changes in the method used to identify and/or record DRDs. Equally, when 
comparing countries, it is important to consider the extent to which national recording 
systems provide data on DRDs that are comparable. The use of Selection D (see Box 1) 
data for Ireland may lead to some issues regarding comparability with the other six 
countries, for which Selection B data were used. If there is substantial variability between 
countries or over time with respect to the degree to which their systems capture cases of 
DRDs, then these differences in recording will confound comparisons between countries. 
Such variability might arise from differences or changes in recording practice (e.g. routine 
use of specific ICD codes on death certificates); coverage of autopsies and/or toxicology 
screening; the sensitivity of the toxicological tests employed; the drugs included in toxicology 
screening; or the national definition of DRD. 
Table 1: Estimated coverage of toxicology, 2004-2014 
Country Coverage 
Denmark  94-100 %  
Estonia  97-100 %  
Finland  100 %  
Ireland  ~100 %  
Norway  ~90 %  
Scotland  100 %  
Sweden  ~100 % 
See country profiles in Appendix  for more details 
 
Note that in a parallel EMCDDA project (England, 2017a; 2017b; 2017c; Giraudon et al., 
2016), which considered a larger range of EU countries, a more detailed examination 
specifically of DRD recording mechanisms was undertaken. In this parallel project: 
• the Inventory of the national Special Mortality Registries in Europe was reviewed with 
a focus on information flow to the General Mortality Register; 
• examples of good practice and collaboration between the general mortality registers 
(GMRs) and special registers (SRs) were identified; 
• coding practices and trends in DRDs in countries were reviewed following the World 
Health Organization (WHO) ICD-10 updates; 
• data on DRDs in a subset of countries were analysed in order to evaluate the use of 
specific codes, such as X44/X64/Y14 codes, and non-specific codes, such as R99, 
X49 and X69, and the use or non-use of T codes. 
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The findings from this parallel project have been published in a separate report (England, 
2017). 
 
 
Table 1 shows the estimated coverage of autopsies of unexplained deaths and associated 
toxicology for the countries considered here. It is apparent that case capture is reasonably 
complete in all of the countries: their high level of case capture may contribute to the 
perception that these countries have higher levels of DRDs than countries for which the 
reliability of data collection is more limited or case capture may be less complete. For 
example, in France, it is suggested that official statistics underestimate the number of DRDs 
by as much as 30-40 % (Janssen, 2009; Janssen, 2010). 
Box 3: The effect of changes in coding practices and toxicological analysis in Sweden 
According to official mortality statistics, the number of DRDs has doubled in Sweden over the last 10 years 
(NBHW, 2015), largely because of an increase in deaths involving opioids (Fugelstad et al., 2016; NBHW, 
2016; Wikner et al., 2014). In a parallel project, colleagues from the Swedish Council for Information on Alcohol 
and Other Drugs (CAN) have undertaken a detailed investigation of the extent to which, if any, changes in 
coding practices and improvements in toxicological analysis have contributed to this apparent increasing trend. 
In Sweden, different indicators are used to monitor DRDs and trends. The two most important are derived from 
the GMR, which is based on causes of death and is an indicator of DRDs. Complementary indicators are based 
on deaths for which forensic toxicological analyses show the presence of illicit drugs or pharmaceutical opioid 
drugs; these do not consider causality and are referred to as ‘drug deaths’ (DDs). CAN’s study shows that there 
have been several changes in coding practices that have had an impact on the apparent trend in DDs and 
DRDs. 
Changes in coding practices 
• From 2007, the recording of more specific information on death certificates resulted in greater scope 
for use of the codes included in the GMR selections for DRDs. 
• Until 2012, tramadol was coded as T39.3, which is not included in the DRD statistics. After 2012, it 
was coded as T40.8, which is included in the DRD statistics. 
• A previously common opioid substance, dextropropoxyphene (DXP), has not been included in the 
Swedish DRD or DD indicators. DXP was removed from the market in March 2011. DXP users are 
likely to have switched to other opioids to replace DXP and deaths involving these other opioids are 
included in the DRD statistics. As a consequence, the Swedish DRD data have, for several years, not 
been strictly comparable with the data from the other European countries, which comply fully with the 
European DRD protocol. 
Improvements in toxicological analyses  
Over time, several improvements in toxicological analyses have been made, which have also had an impact on 
the trends; in summary, ‘the more you search, the more you find’. For example, previously, screening for illicit 
drugs was done at the request of the responsible pathologist, i.e. when it seemed likely, based on 
circumstantial information and autopsy findings, that the decedent had consumed drugs. However, for the last 
eight years or so, routine screening for illicit drugs has become more common. The effect of this was most 
clearly shown for fentanyl, with a doubling of the number of positively detected fentanyl cases when going from 
no screening (only testing under suspicion) to full screening on every forensically investigated death, from 
September 2011. Moreover, technical and analytical improvements have increased the range of drugs 
identified, to include most illicit drugs, and the sensitivity of testing, such that low concentrations of substances, 
not least several opioids, can be detected. As a consequence, the threshold value for positive cases was 
lowered for methadone, oxycodone and DXP.  
The effect of all these changes is that that the magnitude of the increase in DRDs (and in DDs) has been 
exaggerated. Still, the estimated trends, net of these methodological changes, suggest a real increase in DRDs 
because of an increase in opioid-related deaths. Furthermore, the inconsistencies in the Swedish data on 
DRDs also give rise to questions regarding the comparability of the Swedish statistics with other European 
countries, in terms of both specific years and country-specific trends. 
 
For full details of the CAN analysis, see Leifman (2016). 
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It was beyond the scope of this project to consider, in detail, the recording systems used in 
each country and possible changes over time. However, in parallel work, the Swedish 
Council for Information on Alcohol and Other Drugs (CAN) examined data from Sweden’s 
three recording systems to establish (1) whether or not there have been changes over time 
in DRD recording processes and (2) the extent to which such changes contribute to the 
apparent increasing trend in DRDs in Sweden (see Box 3). 
As shown later in the report (see Figure 5), Sweden has experienced a particularly dramatic 
increase in the number of recorded opioid-related DRDs; hence, it is important to understand 
whether this increase is a real one or it is an artefact arising from changes to the national 
recording system. The CAN study demonstrates, very clearly, the importance of considering 
such changes, because, although there appears to have been a real underlying increase, it 
is highly likely that quite subtle changes in coding and toxicological practice have inflated the 
apparent trend. Notable here is Sweden’s non-inclusion of dextropropoxyphene (DXP)-
related deaths in its DRD figures; after DXP was withdrawn from the market in 2011, users 
are likely to have switched to other opioids that are included in the national DRD figures, 
inflating the apparent trend. Thus, the actual year-on-year increase in DRDs is real, but is 
less dramatic than the published figures suggest. 
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4.0: Country comparisons — number of drug-related deaths 
involving opioids and estimates of the size of the population at risk 
 
Figure 1: Number of DRDs by country — total number of DRDs, number with known 
toxicology and number involving opioids — in 2013 
 
Figure 1 shows the total number of DRDs recorded in each country (in 2013, the latest year 
for which complete data are available), along with the number for which toxicological 
screening was reported and the subset of the latter that involved opioids. 
As noted above, opioids account for the vast majority of DRDs in all of the countries 
considered. This general pattern is reasonably consistent over time and the trend in deaths 
involving opioids mirrors the overall trend in DRDs (see Appendices A.1-A.7), 
notwithstanding that there may sometimes be changes in the coverage and extent of 
toxicological screening (see Section 3). 
Figure 2 is based on the EMCDDA Selection B criteria for DRDs (derived from GMRs), 
except for Ireland, which is based on Selection D (derived from a special mortality register 
(SMR)), as are the figures that follow. It shows the proportion of DRDs with known toxicology 
where opioids were present during 2013 (the latest year for which data are available for all 
seven countries); this ranges from 93 % in Scotland to 79 % in Norway. The general trend 
observed over the past decade is that an increasing proportion of DRDs involves opioids, 
with opioids driving the overall trend in DRDs (see the country profiles in Appendices A.1-7 
for details). 
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4.1: Proportion of deaths involving opioids 
Figure 2: Proportion of DRDs with known toxicology where opioids were present, 
2013 
 
 
4.2: Size of the population at risk of drug-related deaths 
As noted in Section 2, the number of individuals at risk of DRD is a key driver of the number 
of DRDs that will be observed in any country. This section considers and compares, as far 
as is possible, the best available and most recent indicators of the size of the at-risk 
population in each of the seven countries. Note that, even where these data are available, 
the definitions and methods used to generate estimates often differ between countries and 
over time. 
As noted earlier, POU prevalence estimates are the preferred indicator of the size of the at-
risk population. The EMCDDA publishes POU prevalence estimates, provided by Member 
States, for three of the countries considered here: Norway, Finland, and Ireland. The most 
recent of these estimates are shown in Table 2. Note that, in accordance with the EMCDDA 
definition (see Box 4), the estimate for Norway excludes those stabilised on opioid 
substitution treatment (OST), estimated at around 7 500 individuals. However, these treated 
opioid users are part of the at-risk population because treatment reduces, but does not 
eliminate, DRD risk (Pierce et al., 2015). The contribution of treatment to reducing risk is 
considered in a later section. Note also that the estimate for Ireland is for an earlier period 
than the estimates for Norway and Finland, and that there are potentially important 
differences in the methodology and/or data sources used to derive the estimates. For 
example, the estimates for Finland, although they use a capture–recapture (CRC) method as 
in many other countries, do not include a national treatment data source; national experts 
suggest that, as a result, the estimates may be higher than expected and may include a 
large number of non-problem opioid users. 
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 For countries where POU estimates are not available, the EMCDDA indicator of problem 
drug use (PDU) prevalence, defined as ‘injecting drug use or regular and/or long-term use of 
opioids, cocaine and/or amphetamines’ (EMCDDA, 2013), might provide a suitable proxy, 
albeit this is imperfect and will apply only in countries where opioid users account for the 
bulk of problem users. The PDU indicator has recently been superseded by the high-risk 
drug use (HRDU) indicator, defined as ‘recurrent drug use that is causing actual harms 
(negative consequences) to the person (including dependence, but also other health, 
psychological or social problems) or is placing the person at a high probability/risk of 
suffering such harms’ (EMCDDA, 2013). Definitions of HRDU, in particular, can encompass 
a far wider group than those specifically at risk of DRD, rendering the indicator potentially 
unsuitable as a denominator; in Denmark, for instance, HRDU estimates include persistent 
users of cannabis (4), a group that does not contribute to the size of the at-risk population 
(EMCDDA, 2016b). 
Table 2 also shows the most recent estimates for PDU/HRDU available via EMCDDA for 
countries without a POU figure and the most recent estimate of PDU published by the 
Information Services Division Scotland (ISD). Note that the estimate for Denmark includes 
approximately 11 000 cannabis users. The estimate for Scotland focuses on opioid use 
(prescribed and non-prescribed) and/or illicit benzodiazepine use. However, national experts 
in Scotland advise that the PDU estimate is a close proxy for POU because the CRC 
sampling framework is unlikely to sample problem benzodiazepine users who are not also 
heroin users. 
 
  
(4) This was possible before 2013, but is no longer recommended in the current data collection.   
Box 4: EMCDDA indicator for the prevalence of problem opioid use 
 
Case definition, in order of preference (recall period: last 12 months): 
 
Use of opioids, including opioid medicines, weekly or more frequently for at least six months of the past 12 
months (alternatively can be measured as 26 days or more in the past 12 months), not according to medical 
prescription.  
OR  
A medical diagnosis according to current DSM (Diagnostic and Statistical Manual of Mental Disorders) or ICD 
criteria, e.g. ‘harmful use or dependence on opioids or opioid use disorder’ (diagnosed in the past 12 
months). 
OR  
Any other best proxy of the above that can be collected at the level of the data source.  
 
Note: opioid users who are stabilised on OST are, if possible, reported separately. 
 
(EMCDDA, 2013)  
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Table 2: Available recent estimates of the prevalence of POU, PDU or HRDU (or IDU)  
Country Year Definition 
Rate (per 
1 000 
aged 15-
64) (a) 
Lower 
limit 
Upper 
limit 
Estimated 
number of 
users 
Lower 
limit 
Upper 
limit Method 
Norway (b) 2013 POU excl. OST (7 500) 2.68 1.99 4.15 9 015 6 708 13 977 TM 
Finland (c) 2012 POU 4.12 3.78 4.49 13 836 12 700 15 090 CR 
Ireland (d) 2006 POU 7.2 6.2 8.1 20 790 18 136 23 576 CR 
Denmark (
e) 2009 HRDU incl. cannabis (11 000) 9.12 8.59 9.65 33 074 31 151 34 997 CR 
Sweden (f) 2007 PDU 4.9 n.a. n.a. 29 513 n.a. n.a. TP 
Scotland (g
) 2012/3 
PDU (opioids and/or 
benzodiazepines) 17.4 16.9 17.9 61 500 59 900 63 300 CR 
Estonia (h) 2009 IDU 9 7 17 5 362 3 906 9 837 CR 
(a) Rate for Estonia is per 1 000 population aged 15-44 years. 
(b) Gjersing and Sandøy. 
(c) Ollgren et al. (2012). 
(d) Kelly et al. (2009). 
(e) Denmark National Focal Point (unpublished data). 
(f) Statens Folkhälsoinstitut (2011). 
(g) ISD (2016a). 
(h) Uusküla et al. (2013). 
CR, capture–recapture; excl., excluding; IDU, injecting drug use; incl., including; TM, treatment multiplier. TP Truncated 
Poisson N.k. not known; n.a. not available  
Source: (EMCDDA, 2016b) 
 
POU/PDU/HRDU estimates are not available for Estonia. The closest available proxy is a 
CRC estimate for the prevalence of injecting drug use (shown in Table 2). Note that, 
although treatment demand data suggest that almost all opioid users in Estonia inject, 
national experts advise that the population of injecting drug users, and thus the estimate, 
also includes stimulant users. Therefore, the number of problem opioid users is likely to be 
smaller than the estimated number of injecting users. 
The estimates presented in Table 2 use different case definitions and methodologies, and 
relate to different periods. They are also subject to varying degrees of imprecision. 
PDU/HRDU estimates, in particular, will overestimate the size of the population that is at risk 
of DRD involving opioids. Therefore, the estimates provide a gross estimate of the size of 
the population at risk but are not capable of supporting precise between-country 
comparisons of DRD risk. Nevertheless, they illustrate the potential magnitude of differences 
between countries in the size of the populations at risk of DRD. 
Considering the crude adjustments and assumptions proposed in Box 5, and 
notwithstanding that the available estimates relate to different years: 
• It is likely that Estonia has the smallest number of problem opioid users — fewer than 
the estimated 4 000-10 000 injecting drug users. 
• There is a group of countries within the mid-range with regard to problem opioid 
users: Finland (13 000-15 000), Norway (roughly 14 000-21 500), Ireland (18 000-
23 500) and Denmark (high-risk drug (excluding cannabis) users: roughly 20 000-
24 000). For many of these countries, the confidence intervals (CIs) surrounding the 
estimates overlap. 
• Sweden may have a somewhat larger at-risk population (29 500 problem drug 
users), albeit this is an overestimate because it relates to PDU rather than POU. 
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• The PDU estimate for Scotland (60 000-63 000 users), which is a good proxy for 
POU, suggests an at-risk population that is perhaps double that for Sweden, around 
three times as large as for most of the other countries considered and at least six 
times as large as for Estonia. 
 
 
 
4.3: Trends in the size of the population at risk of drug-related death 
Section 4.2 illustrates the difficulty of comparing countries with respect to the size of their 
corresponding at-risk populations. This difficulty becomes more acute when attempting to 
compare trends over time. 
Even if serial prevalence estimates are available, the case definition for these not only differs 
between countries, but can also change over time within countries. For example, the 2007 
estimate for Sweden related to ‘problematic abuse diagnosis according to ICD code (F11-16; 
F18-19; O35.5; P04.4; T40; T43.6; Z50.3; Z71.5)’, whereas previous estimates related to 
injecting over the past year or daily use in the past month (Folkhälsomyndigheten, 2014). 
Even if the case definition is consistent over time, by their nature, prevalence estimates may 
not be sufficiently precise to allow a comparison of an estimate at one time point with an 
estimate at another point in time. For example, for Estonia, serial estimates, for 2004-2009, 
are available for the prevalence of injecting drug use and these employ a reasonably 
consistent methodology (Uusküla et al., 2013): however, although the mid-point estimates 
for these may indicate declining prevalence, if the associated CIs are taken into account the 
situation may be interpreted as more stable. 
Box 5: Improving the comparability of estimates 
Although the exercise is highly speculative, it may be helpful to consider whether or not it is possible to make, albeit 
crude, adjustments to or assumptions about some of the estimates presented in Table 2 to improve their 
comparability:  
• Norway: the 2013 POU estimate (9 015, 95 % CI 6 708-13 977) excludes those in OST, estimated to be 
around 7 500 individuals. Although the national experts advise that an accurate estimate cannot be obtained 
by combining the two figures, this combination would imply a very rough estimate of the size of the 
Norwegian at-risk population of somewhere in the region of 14 000 to 21 500 individuals (lower/upper CI for 
the POU estimate + number in OST).  
• Finland: a 2012 POU estimate (13 000 to 15 000) is available. 
• Ireland: a 2006 POU estimate (18 000 to 23,500) is available. 
• Denmark: the 2009 HRDU estimate (33 000) includes around 11 000 cannabis users who, as noted above, 
do not contribute to the at-risk population. Subtracting these would imply a rough estimate of the Danish at-
risk population of around 20 000 to 24 000 individuals, although this rough estimate will still include non-
opioid users who meet the Danish HRDU definition, so it remains an overestimate of the denominator for 
opioid DRDs.  
• Sweden: there is insufficient information regarding the 2007 PDU estimate (29 500) to attempt an 
adjustment; it is likely to overestimate POU prevalence. 
• Scotland: national experts advise that the 2012/2013 PDU estimate (60 000 to 63 000) is a very close 
proxy for POU because the CRC sampling framework is unlikely to sample problem benzodiazepine users 
who are not also heroin users. 
• Estonia: the 2009 estimate shown is for injecting drug use (4 000 to 10 000). Treatment demand data 
suggest that almost all opioid users in Estonia inject. However, national experts advise that the population of 
injecting drug users, and thus the estimate, also includes stimulant users. Therefore, the number of problem 
opioid users is likely to be smaller than the estimated number of injecting users. 
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Moreover, the methods used to derive estimates may change over time. For example, 
Finland has produced POU estimates for 2005 and 2012 that suggest a substantial increase 
in prevalence; however, the later estimate is based on a different approach to modelling and 
incorporates an improved range of CRC sources. National experts have indicated that, 
although the later estimate may be a more accurate reflection of the size of the at-risk 
population, it is not comparable with the earlier estimate (and may not be comparable with 
the estimates for other countries). 
 
 
Although it is correct that countries should improve the specificity of case definition and the 
methods used to derive estimates, our conclusion is that, for the countries considered here, 
it is not possible to make meaningful comparisons between the trends in the size of the at-
risk population and the trends in the number of DRDs recorded. 
 
4.4: Number of deaths involving opioids 
Figure 3 shows, for 2013, the number of recorded deaths with known toxicology in each 
country where opioids were present. Scotland stands out as a country with a similar 
population size to countries such as Denmark, Finland and Norway, but a much greater 
number of opioid-related deaths; however, this should be considered in the context of the 
size of the population at risk of DRD, as highlighted in previous sections. 
Box 6: Cohort studies 
Cohort studies, which examine DRDs among groups of drug users of known size and with known characteristics, were 
proposed as an alternative approach to understanding differences in DRD risk between countries and over time. Twenty-
three potential studies relating to drug user mortality in the countries/regions considered in this report were identified 
based on a non-systematic search of available databases and bibliographic searches of the published literature (Merrall 
et al., 2012; Merrall et al., 2013; Copeland et al., 2012; Bloor et al., 2008; Bird, 2010; Cornish et al., 2010; Macleod et al., 
2010; McCowan et al., 2009; McKeganey et al., 2008; Kimber et al., 2010; Neufeind et al., 2011; Clausen et al., 2008; 
Clausen et al., 2009; Ødegård et al., 2007; Ravndal et al., 2010; Davstad et al., 2011; Nyhlén et al., 2011; Stenbacka et 
al., 2010; Fugelstad et al., 1997; Onyeka et al., 2014; Arendt et al., 2011; Lynn et al., 2009, Lyons et al ., 2010). These 
were screened according to the following criteria (studies excluded at each level did not progress to screening at further 
levels): 
1. the study reports findings for one of the countries/regions of interest; 
2. the study reports a DRD crude mortality rate (CMR) — 16 were excluded on this basis; 
3. the cohort recruitment and observation at least overlaps with the period of interest (to avoid excessive 
confounding because of epoch); 
4. the study employs a clear case definition comprising active drug users during the period of observation (to 
avoid ‘dilution’ of risk in historically recruited cohorts that include no-longer-active drug users) — an additional 
three were excluded on this basis; 
5. the study specifies the type of drug use among the cohort (because, for example, we should not compare DRD 
risk in a cohort of cannabis users with risk in a cohort of heroin users). 
 
The remaining four studies related to Scotland and to Norway. Within-country cohorts were the same or overlapping, 
hence one study from each country was selected for consideration (Merrall et al. (2012) and Clausen et al. (2008), 
respectively). Both studies recruited from treatment settings (Scotland, 1996-2006; Norway, 1997-2003), but, in contrast 
to the Scotland study, the Norway study included a subset of persons who did not actually enter treatment (not included 
here). The Scotland study reported a DRD rate (during- and post-treatment rates combined) for opiate users of 4.4 (95 % 
CI 4.1-4.6) per 1 000 person years; information is not available on the number of DRDs or the duration of observation for 
treatment and non-treatment periods. The Norway study reported a during-treatment rate of 4 (95 % CI 0-8) and a post-
treatment rate of 21 (95 % CI 17-25) per 1 000 person-years, equivalent to a (derived) rate of around 6.7 per 1 000 
person-years for treatment and post-treatment periods combined. 
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Figure 3: Number of deaths with known toxicology where opioids were present, 2013 
 
 
Available prevalence estimates, although an imperfect indicator of POU prevalence, suggest 
that the at-risk population is Scotland is much larger, perhaps two or three times larger, than 
in most of the other countries considered here (see Section 4.2). These estimates also 
suggest that Sweden has the second largest at-risk population, followed by Denmark, 
Ireland, Norway and Finland, and that Estonia is likely to have the smallest at-risk 
population. 
 
Figure 4 compares the mean number of opioid-related deaths in each country with the 
prevalence estimates described in Box 5. This shows that, although the comparison is 
inevitably crude, does not reflect the imprecision of these estimates and is highly 
speculative, in the most general terms, the number of opioid-related DRDs observed in each 
country is broadly consistent with expectations based on the best available indicator of the 
size of their corresponding at-risk populations. 
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Figure 4: Mean annual number of opioid-related deaths (2009-2013) vs. best available 
estimates of problem opioid users (or a proxy thereof) 
 
 
 
4.5: Trends in deaths involving opioids 
Figure 5 shows the trend from 2004 to 2014 in the number of deaths involving opioids that 
were recorded in each country. Again, these are based on the EMCDDA Selection B 
criterion (derived from a GMR), except for Ireland which is based on Selection D (derived 
from an SMR). 
 
Figure 5: Trends in the number of DRDs involving opioids, 2004-2014 
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In many of the countries considered (Denmark, Finland, Ireland, Norway, Scotland and 
Sweden), there was an increase in the number of DRDs involving opioids during the early 
part of the time series, until around 2008/2009. An interruption in this trend is apparent for 
several countries around 2010, the period of the European ‘heroin drought’ observed in 
some countries (Ahmad and Richardson, 2016; EMCDDA, 2011b), with a return to the pre-
2010 level thereafter; only in Sweden was there a clear and sustained increase after 
2008/2009 in the annual number of recorded DRDs involving opioids. 
The ‘heroin drought’ is an example of an environmental factor that may affect both the 
number of users actively ‘at risk’, if decreased availability results in some individuals using 
less often or not at all, and the degree of risk involved, if fluctuations in availability result in 
variable purity, as purity is moderately associated with the occurrence of DRDs (Darke et al., 
1999). Estimates of global opium production, from the United Nations Office on Drugs and 
Crime (UNODC, 2015), suggest a relatively short period of reduced production, starting 
around 2009/2010. It is not clear why this might have had a more sustained effect on DRDs. 
However, it is plausible that periods of low production might have longer term impacts on 
availability and, also, that changes in users’ behaviour during periods of restricted supply 
might have an impact on their DRD risk; for example, they may access treatment and remain 
in treatment thereafter. It is notable that some countries, e.g. the United Kingdom (ONS, 
2016; National records of Scotland, 2016), have seen a more recent return to the increasing 
DRD trend that preceded the European ‘heroin drought’. Data on purity were available for 
some of the countries considered here and are presented in the country profiles in Appendix. 
In Finland, Ireland and Scotland, the most recent available EMCDDA figures (up to 2014) 
indicate only a very slight (around 5 %) increase from 2008/2009 levels, and in Denmark and 
Norway the figures suggest that in recent years there have fewer deaths than during 
2008/2009. A full time series is not available for Estonia but, despite increases in 2011 and 
2012, the number of deaths recorded during 2014 was similar to that recorded in 2010. 
Thus, for most of the countries considered here, for the period for which EMCDDA data are 
available, despite an earlier increase (between 2004 and 2008/2009), there has been no 
apparent increase in DRDs involving opioids in recent years. However, Sweden is an 
exception here, although it is likely that the apparent increase in recorded deaths in this 
country is, in part, a consequence of changes in the method of recording DRDs (see 
Section 3). The most recent data for Scotland (i.e. for 2015) suggest that the number of 
deaths has been increasing again, substantially, each year since 2013. 
As noted above (Section 4.3), it has not been possible, on the basis of available data, to 
place the trend in the number of opioid DRDs in the context of the trend in the size of the at-
risk population. 
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5.0: Country comparisons — risk factors for drug-related deaths 
 
There is insufficient precise information available to enable a comparison of DRD risk 
between countries or to establish whether or not observed risk has changed over time. 
However, the project has explored a series of factors that may, plausibly, influence risk, in 
order to determine whether or not there might be evidence that countries differ with respect 
to these factors and whether or not these vary over time. The set of risk factors considered 
here is not exhaustive, but reflects those drivers that might be assessed on the basis of 
available information published by the EMCDDA. There are, of course, additional factors that 
could not be assessed here and that may contribute to differences in the level of risk in 
different countries, for example the prevalence of comorbidity in the at-risk population or the 
influence of prison release, and different responses to these factors. The time after release 
from prison is known to be a period of high DRD risk (Farrell and Marsden, 2008; Merrall et 
al., 2010). Although it has been suggested that this factor is not sufficient to explain 
between-country differences in mortality levels (Waal and Gossop, 2014), countries may 
differ with regard to interventions designed to reduce risk during this period; however, there 
is no systematically collected dataset that would inform a comparison of this. 
 
5.1: Treatment factors 
Treatment might potentially influence risk via two primary dimensions. First, differences in 
the pattern of treatment might increase risk: for example, more and briefer treatment 
episodes may increase treatment transitions, which elevate risk (Pierce et al., 2016), or an 
emphasis on abstinence-focused treatment might increase the number of individuals 
exposed to elevated risk on relapse. Second, insofar as being in OST is associated with a 
reduction in individual risk, the extent to which treatment services ‘capture’ the at-risk 
population is likely to influence the degree of risk in that population (White et al., 2015). 
There are no standard indicators available to assess the first of these factors, but the second 
may be explored, to some extent, via EMCDDA figures describing the number of persons in 
OST in each country, or estimates thereof (EMCDDA, 2014 (for Scotland); EMCDDA, 
2016b). These are also discussed in the country profiles provided in Appendix. Differences 
in the pattern and introduction of OST in the Nordic countries have been described 
elsewhere (Skretting and Rosenqvist, 2010). 
In most of the countries considered here, there has been a general increase in the number 
of persons engaged in OST. Denmark and Estonia, where the numbers are relatively stable 
throughout most of the time series, are exceptions. Data for only two time points (2006 and 
2007) could be located for Scotland. However, the implications of the increasing trend are 
difficult to interpret in the absence of information about trends in the size of the POU 
population. If the latter is stable or has decreased, an increase in OST numbers would imply 
a possible reduction in population-level risk among problem opioid users. If POU prevalence 
has increased, then it is not possible to determine whether or not the increasing trend for 
OST has kept pace. In some cases, local intelligence suggests that very good OST 
coverage has been achieved (see, for example, Appendix A.5, Norway summary); however, 
it has not been possible to make systematic comparisons between countries. The EMCDDA 
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publishes data on OST coverage for just one of the countries considered here: Norway 
(EMCDDA, 2016b). 
Figure 6 shows the number of persons in OST in each country during 2007, the most recent 
year for which figures are available for all of the countries considered (note that more recent 
data are available for most countries and that these indicate an increase in the numbers in 
OST, e.g. in Norway). The number of people in OST appears to be only weakly related to the 
estimates of the size of the at-risk population, discussed in Section 4.2, which might imply 
that differences in OST coverage may result in higher levels of population risk in some 
countries than in others. It is not possible to draw firm conclusions in this regard because of 
variability in the definitions on which prevalence estimates are based and because different 
periods are considered. A further difficulty here is that available data are not sufficient to 
determine the extent to which the OST population is representative of those subgroups 
within the wider at-risk population, which may be at greater or lesser risk. It should also be 
considered that in countries where OST covers a higher than average proportion of problem 
opioid users, there may still be a larger than average number of ‘out-of-OST’ problem opioid 
users and thus a larger number of ‘at-higher-risk’ problem opioid users. 
 
Figure 6: Number of persons in OST in each country during 2007 
 
 
5.2: Harm reduction 
Across all of the featured countries, a number of effective harm-reduction interventions have 
been mainstreamed within routine practice over the past 30 years (Table 3). For example, 
needle and syringe provision (NSP) or injecting equipment provision (IEP) is now well 
established within all countries. The extent of NSP/IEP coverage in each country is less 
clear, however, with only crude estimates available regarding how many syringes are 
accessed by people who inject drugs (PWID) each year. 
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Treatment via OST is also widespread and known to reduce the risk of death among PWID 
(Degenhardt et al., 2011; Pierce et al., 2016). Methadone-based OST is available in every 
country to varying degrees, accounting for almost all OST prescriptions in Estonia and 
Ireland. In contrast, countries such as Norway, Denmark and Sweden no longer recommend 
methadone as a first choice OST option and have policies in place aimed at increasing use 
of buprenorphine- or buprenorphine-/naloxone-based medicines. 
Other harm-reduction approaches have been proposed and adopted in some countries, in 
particular supervised injecting facilities (SIFs) and heroin assisted treatment (HAT). Although 
it is difficult to quantify their overall impact, there is evidence to suggest that SIFs are 
associated with reductions in overdose-related mortality (Marshall et al., 2011). Far from 
being mainstreamed, there are examples of SIFs in many European countries including 
Denmark and Norway (EMCDDA, 2016c). There are no such facilities in the United Kingdom 
or Ireland; however, formal proposals are now in place to open such venues in Dublin 
(Ireland) and Glasgow (Scotland). The adoption of HAT is less common and is available in 
only one of the seven included countries (Denmark). The number of patients engaged with 
the five HAT clinics in Denmark is limited each year by funding, but had risen to 300 by 
2013. The overall effectiveness of HAT, at a population level, is unclear; however, there are 
currently clinical trials under way that aim to determine its benefits in reducing drug-related 
harm, including overdose (EMCDDA, 2012a). 
Table 3: Availability of harm-reduction interventions 
Country  
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Denmark  ✓ ✓ × ✓ ✓ ✓ ✓ 
Estonia  ✓ ✓ × ✓ × × ✓ 
Finland  ✓ ✓ ✓ ✓ × × × 
Ireland  ✓ × ✓ ✓ × × ✓ 
Norway  ✓ ✓ ✓ ✓ ✓ × ✓ 
Scotland  ✓ ✓ ✓ ✓ × × ✓ 
Sweden  ✓ ✓ ✓ ✓ × × × 
See country profiles in Appendix for more details 
 
Lastly, there was good evidence available from the majority of the seven countries about 
their implementation of take-home naloxone (THN). With the exception of Finland, all 
featured countries provide THN at some level, ranging from large programmes with national 
coverage (e.g. Scotland, Norway) to small-scale experimental pilot programmes which are 
very much in their infancy (e.g. Ireland). Bird et al. estimate that national THN schemes 
should aim to issue at least nine times as many THN kits as there are opioid-related deaths 
per annum, and that the optimum level is 20 times as many (Bird et al., 2015a). Scotland’s 
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national programme achieved its minimum threshold of 3 600 per annum in its second year 
(2012/2013) and its optimum level by year five (2015/2016). Since its inception in 2011, the 
national naloxone programme in Scotland has now distributed almost 30 000 THN kits, 
which have been associated with a 36 % reduction in opioid-related deaths in the four weeks 
following prison release (Bird et al., 2016). 
The impact of THN on DRD numbers and trends in the other countries studied in this project 
is unclear thus far, but is likely to be modest given the small number of kits distributed. 
Estonia has come closest to achieving its minimum threshold of approximately 850 kits per 
annum. In addition, Norway is on course to supply its own minimum threshold of 1 800 per 
annum, having supplied over 2 000 kits in the first 18 months of its national programme, 
which commenced in spring 2014. 
 
5.3: Behavioural factors 
The extent of risky behaviour among at-risk populations is another factor that influences 
differences in population-level DRD risk. Injecting is a known behavioural risk (Gossop et al., 
2002; Pierce et al. 2016), as are polysubstance use (Darke and Zador, 1996; Pierce et al., 
2016) and the use of specific opioids such as fentanyl (Mounteney et al., 2015). Experience 
of a prior non-fatal overdose is also likely to elevate risk of DRD (Caudarella et al., 2016). 
The EMCDDA treatment demand indicator potentially provides a source of information about 
differences in risk behaviour with respect to injecting and provides some information 
regarding trends in the use of different classes of opioid (heroin vs. methadone vs. other 
opioid drugs). Information about the extent to which DRDs involve polysubstance use are 
also available, but for a more limited number of countries, and long-term trend data not being 
available. 
 
Injecting 
Figure 7 shows trends, for six countries, in the proportion of opioid-using treatment entrants 
who reported injecting (EMCDDA, various years5). Elsewhere it is reported that, during 
2014/2015, 47 % of heroin-using individuals who sought treatment in Scotland had injected 
heroin and that this proportion has been relatively stable (ISD, 2016b). The rate of injecting 
among opioid-using treatment entrants in Estonia, Finland and Norway is higher than in 
other countries and is lowest in Ireland and Denmark, with signs of a substantially increasing 
rate of injecting in Denmark. If treatment entrants are representative of the wider at-risk 
population, this may imply elevated DRD risk among the at-risk population in the former 
group of countries and an increasing risk in Denmark. 
 
5 The figures were pulled from the reports for various years. 
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Figure 7: Trend in the percentage of users injecting the primary drug among primary 
opioid users presenting for treatment, 2003-2014 
 
 
Type of opioid 
Figure 8 shows, for five countries, the proportion of opioid-using clients entering treatment 
according to the type of opioid used (EMCDDA, 2012b). Elsewhere it is reported that opioid 
misuse among treatment entrants in Scotland is dominated by heroin (ISD, 2016b), the 
Scottish situation being most similar to that in Ireland. There are clear differences between 
countries with respect to the extent of use of ‘other opioids’, which account for almost all 
opioid misuse among treatment entrants in Finland and Estonia and for substantial 
proportions in Denmark and Sweden. Specifically, fentanyl use is well known to be an 
endemic problem in Estonia, but is not common elsewhere in Europe (Mounteney et al., 
2015). The use of fentanyl carries a particular risk because it has a higher potency than 
heroin, particularly the highly potent 3-methylfentanyl analogue, which is commonly misused 
in Estonia (Ojanperä et al., 2008); thus, we expect much higher levels of risk among problem 
opioid users in Estonia. Buprenorphine is the opioid most commonly misused in Finland 
(Forsell and Nurmi, 2013), a pattern that emerged in the early 2000s, with injecting being the 
most common route of administration (Partanen and Maki, 2004), almost entirely displacing 
the misuse of heroin, with concurrent alcohol and/or prescription drug misuse being common 
(Uosukainen et al., 2013). Illicit use of buprenorphine appears to have become more 
common among opioid users in Sweden (Hakansson et al., 2007). 
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Figure 8: Proportion of clients entering treatment for opioids by country and type of 
opioid misused, 2010 
 
 
Toxicology data, where available, may be informative for understanding differences in the 
types of opioid use involved in DRDs. For example, the most recently available data from 
analysis of countries’ DRD 2015 statistical returns to the EMCDDA highlights that the 
majority (60 %) of opioid DRDs in Denmark involve methadone and a minority (34 %) involve 
heroin, whereas in Norway methadone and heroin were each involved in around one third of 
opioid DRDs and in Ireland each was involved in around a half. Data provided by Scotland 
indicate a similar pattern to that in Ireland, albeit with a slightly smaller proportion of opioid 
DRDs involving methadone and a slightly larger proportion involving heroin. Elsewhere, it is 
reported that DRDs in Denmark and Sweden primarily involve methadone (this is in contrast 
to the patterns of use reported among treatment entrants); in Norway most DRDs involve 
heroin; and in Finland most involve buprenorphine (Gjersing et al., 2013; Simonsen et al., 
2015), although more recent analysis suggests more buprenorphine-related than 
methadone-related deaths in Sweden (Leifman, 2016). Based on a series of studies of 
DRDs that include the Nordic countries considered here (Denmark, Finland, Norway and 
Sweden), published between 1984 and 2015, Simonsen et al. (2015) concluded that 
methadone, buprenorphine, fentanyl and tramadol have, to a large extent, replaced heroin. 
Fentanyl or 3-methylfentanyl is involved in the majority of DRDs in Estonia, having displaced 
poppy straw from around 2002 (Tuusov et al., 2013). 
Polysubstance use 
Toxicology data may also be informative in respect of DRDs involving polysubstance use 
(drugs and/or alcohol), which is known to elevate DRD risk. The most recently available data 
from the EMCDDA suggest that the proportion of opioid DRDs involving other (non-opioid) 
substances was as follows: 30 % in Norway; 56 % in Denmark; 65 % in Ireland; and 92 % in 
Scotland. However, elsewhere it is reported that almost all DRDs in Norway involve polydrug 
intoxication (Gjersing et al., 2013). In Finland, it has been observed that one third of DRDs 
involving buprenorphine misuse also involve alcohol (Häkkinen et al., 2014a) and there is 
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also evidence of the involvement of concurrent use of opioids, particularly buprenorphine, 
with pregabalin (Häkkinen et al., 2014b). National experts in Finland suggest that 80 % of 
DRDs involve multiple drugs, with few attributed to poisoning as a result of consumption of a 
single drug, and that there has been little change in the trend of polydrug involvement in 
DRDs over time (see Appendix A.3). Polydrug use is common among at-risk drug users in 
Sweden (Leifman, 2015) and multiple drugs are often found in poisoning-related deaths 
(Fugelstad et al., 2010). The CAN analysis (Leifman, 2016; see Box 3) indicates that 
combined use with benzodiazepines may have contributed to the increase in opioid DRDs. 
 
 
5.4: Demographic factors 
Cohort studies suggest that opioid users’ risk of DRD increases with increasing age (Pierce 
et al., 2015), perhaps more markedly for deaths also involving alcohol (McAuley and Best, 
2012) or methadone (Gao et al., 2016). There may also be synergistic effects of age and 
hepatitis C virus (HCV) infection (Merrall et al., 2012). Thus, although the number of older 
users in the POU population may dwindle because of death or recovery, a population of 
older problem opioid users is likely to have a higher risk of DRD than a younger population. 
Figure 9: Trend in mean age at DRD (all DRDs) 
 
Figure 9 shows the trend in mean age at DRD in the featured countries; for Scotland, the 
mean age was not available and the median is substituted here (NRS, 2016). Data specific 
to opioid DRDs are not available, but the data are dominated by such deaths. Although non-
opioid DRDs are a minority, if these occur primarily among relatively young drug users then 
the age trend for opioid DRDs may be more pronounced than Figure 9 suggests. 
In recent years, in most countries the average age at DRD is around 40 years. In Ireland, it 
is slightly younger and in Estonia younger still. Denmark shows the oldest average age for 
DRD, at around 48 years. 
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In several countries (Denmark, Norway, Scotland, Ireland and Estonia) the average age at 
DRD appears to have increased, which is supported by analysis of age by era shown in the 
country-specific reports (Appendices A.1-A.7). This is consistent with the existence of an 
ageing population of problem opioid users. Although the Selection B (GMR) data for Finland 
shown here do not show any trend for an increasing mean age at death, the Finnish Special 
Registry indicates that the mean age of DRD is rising in line with other European countries. 
The national experts for Finland suggest that the differences here are likely to be explained 
by the GMR’s inclusion of older adult deaths coded as ‘drug poisoning’ but with no history of 
drug misuse. Note that ‘mean age’ may disguise important differences in the age distribution 
of at-risk drug users; for example, Swedish experts suggest that their at-risk population 
exhibits a bimodal distribution, comprising younger and older users but with few in the 
intermediate age groups. 
It would be informative to consider information about age at DRD in the context of wider 
indicators of the age of the POU population. EMCDDA treatment demand data were 
considered as a possible information source here, but routinely published data do not 
distinguish between the age of POU and non-POU. However, an earlier study of EMCDDA 
treatment demand data (Barrio et al., 2013) provides information for three countries, on 
trends (from 2000 to 2009) in the age of heroin users seeking treatment, that is highly 
consistent with the information presented in Figure 9. Mean age increased in both Denmark 
and Ireland over this period, but was more stable in Sweden. On average, users in Denmark 
were older and users in Ireland were younger. 
 
 
5.5: Prevalence of blood-borne viruses 
 
Table 4: Prevalence of blood-borne virus infection among people who inject drugs 
(2010-2016) 
 Country HCV HBV HIV 
Denmark  75 %  35 %  < 5 %  
Estonia  76-90 %  3-22 %  ~50 %  
Finland  74 %  1.2 %  —  
Ireland  68 %  —  —  
Norway  64 %  35 % 
(Oslo) 
2.4 %  
Scotland  58 %  —  1.9 %  
Sweden  60-80 % — — 
See country profiles in Appendix for more details 
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Blood-borne virus (BBV) infections, in particular HCV infection, are highly prevalent among 
opioid users, and injecting is the main route of transmission (Giraudon, 2016b). An increase 
in the prevalence of BBV infections in the at-risk population may, therefore, be a factor in 
countries with high or increasing DRD rates. Having an HCV diagnosis is associated with an 
increased risk of DRD among PWID (Merrall et al., 2012; Vajdic et al., 2015) and drug-
related mortality is a major contributor to the overall excess mortality in HCV patients 
achieving sustained viral response post treatment (Innes et al., 2016). High rates of death 
have also been reported among PWID who were positive for human immunodeficiency virus 
(HIV) (Green et al., 2012; Mathers et al., 2013). Therefore, it is plausible that more BBV 
infections in a population at risk could signify more comorbidity in that population and a 
higher risk of DRD. 
Overall, prevalence of HCV infection among PWID across the seven countries ranged from 
60-90 %. The lowest rates were reported in Scotland (58 %) and potentially higher rates 
were reported in Estonia and Sweden (80-90 %). It is notable that Estonia has a very high 
HIV prevalence, although this is decreasing. Comparability of BBV prevalence estimates 
between countries should be made cautiously, though, given the variation in methodologies 
used to collect such data. For example, infectious diseases related to drug use are likely to 
be underdiagnosed in Denmark, since a large proportion of PWID are not regularly tested. 
Moreover, the most recent HCV and HIV prevalence estimates from Norway are based on 
testing carried out within an OST service and are therefore likely to underestimate levels of 
infection within the wider population of opioid users. 
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6.0: Findings, conclusions and recommendations 
 
6.1: Summary of findings 
In many of the seven countries, there was an increase in the number of DRDs, specifically 
opioid DRDs, between 2004 and 2008/2009. There was an interruption to this increasing 
trend in most countries during 2010, the period of the European ‘heroin drought’ (EMCDDA, 
2011b; Ahmad and Richardson, 2016), with little sign of an increase in DRDs thereafter. 
However, there are signs of a more recent increase in DRDs, in some countries, after the 
period considered here. Only in Sweden are there clear signs of an increase in the number 
of recorded DRDs throughout the period considered and after 2010. The trend for Sweden 
has been exaggerated by changes in recording practice and toxicology screening, and the 
Swedish baseline has been underestimated by the exclusion of DXP (see Box 3); however, 
despite this, Swedish national experts conclude that there was an underlying increasing 
trend, albeit of lesser magnitude (Leifman, 2016). 
In the absence of information to support accurate comparisons of risk, Section 5 considered 
a range of factors that may influence risk. These are not exhaustive, being limited to those 
that are reasonably accessible via data published by the EMCDDA. They relate to the 
availability of treatment and harm-reduction interventions; risk associated with drug use 
behaviour; risk associated with key demographic factors (age); and the prevalence of BBVs. 
Here, the clearest differences in risk relate to demographic (age) and behavioural (opioid 
type and injecting) risk. 
• Treatment: there is some evidence of variations between countries with respect to 
treatment coverage, insofar as the number of people engaged in OST is only weakly 
related to a ‘best approximation’ of the number of problem opioid users in each 
country. In the absence of trend data on the size of the POU at-risk population, it is 
not possible to assess the potential effect that changes in the size of the OST group 
exert on DRD trends. Moreover, there is a lack of information on the delivery of 
treatment, dimensions of which are likely to modify a treatment’s protective effect 
with regard to DRD; for example, brief-duration OST will provide less of a protective 
effect than prolonged OST. 
• Harm reduction: most of the countries considered here provide core harm-reduction 
interventions, including THN. For these countries, there is insufficient evidence to 
conclude that variations in the availability of harm-reduction interventions exert an 
impact on differences in DRD risk. 
• Drug use behaviour: there is reasonably strong evidence of between-country 
differences in drug use behaviour that are likely to contribute to differences in DRD 
risk. These include variations in the rate of injecting among known populations of 
opioid users and the use of different opioid types. There is weaker, and in some 
cases contradictory, evidence of between-country variation in the involvement of 
polydrug use (that includes opioids) in DRD. 
• Demographic risk: age is a known risk factor for DRD. For many of the countries 
considered here, there is evidence of an increase in the age at DRD among opioid 
DRD decedents and more limited evidence (derived from treatment settings) that the 
POU population in some countries is ageing. In addition, there is evidence of 
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between-country differences in the age at DRD among opioid DRD decedents that is 
consistent with differences observed via the treatment indicator. This suggests both 
that age-related risk is increasing in some countries and that there are between-
country differences in age-related risk. 
• Prevalence of BBVs: there is some evidence of differences between countries in 
rates of BBV infection, which may elevate DRD risk. However, comparisons should 
be made with caution, given variation in the methods used to assess infection rates. 
 
Section 3 discussed the possible influence of the mechanisms that countries use to identify 
and record DRDs. Clearly, if recording is substantially incomplete, then the number of DRDs 
recorded by published statistics will be an underestimate. In addition, changes over time in 
the way that DRDs are recorded may exaggerate any underlying upwards or downwards 
trends in the number of DRDs that actually occur. All of the countries considered here have 
sophisticated counting systems for DRD, for which local experts regard case capture to be 
reasonably complete. However, experts in Sweden have demonstrated the discernible effect 
that even subtle changes to their national recording system may have had in exaggerating 
the underlying increase in the number of DRDs. 
 
6.2: Conclusions 
Available data do not support precise comparison of DRD rates, and thereby DRD risk, 
between the seven countries, or of trends in DRD rates. Thus, although the number of DRDs 
is broadly proportional to the likely number of at-risk individuals, it is not possible to conclude 
with any certainty whether or not the number of DRDs in some countries is larger than would 
be expected, taking into account the size of their at-risk populations. In addition, it is not 
possible to determine whether changes in the number of opioid DRDs are driven by 
increased POU prevalence or by changes in DRD risk among problem opioid users. It 
should be noted that, if POU prevalence is declining, then even a stable opioid DRD trend 
may reflect increasing risk; this scenario is plausible where there is an ageing, dwindling, 
population of problem opioid users. 
It is likely that several of the risk factors considered here have driven trends in DRDs, and 
that they may explain differences between countries’ DRD rates, if such differences exist. 
However, it is unlikely to be possible to identify a single, primary explanatory factor. It should 
be recognised that (1) there may be complex interactions between drivers; and (2) upwards 
and downwards drivers will operate simultaneously. Thus, downwards drivers, such as 
improving the coverage of OST or the availability of THN, will operate at the same time as 
upwards drivers, such as increasing age in the POU population (Pierce et al., 2015). The 
effect of upwards drivers of risk may be magnified by synergistic interactions between, for 
example, age and alcohol use (McAuley and Best, 2012), methadone consumption (Gao et 
al., 2016) or HCV infection (Merrall et al., 2012). 
In the light of the above observations, given the absence of counterfactual evidence, even 
where the number of DRDs is increasing, it should not be assumed that interventions 
designed to reduce DRDs have not been successful. Indeed, it is likely that the situation 
would be significantly worse without such interventions. 
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 6.3: Recommendations 
Most DRDs involve opioids and opioids have driven the trend in DRDs in the countries 
considered. Increasing age among problem opioid users may be one important driver of 
increasing risk in this population, but it is not possible, based on the EMCDDA DRD 
indicator, to distinguish between opioid- and non-opioid-related deaths with respect to 
decedents’ age (or gender). 
Recommendation: additional specificity regarding the age of opioid versus non-opioid 
DRDs would aid interpretation of DRD trends. In addition, further analysis of the other 
EMCDDA indicators about the wider population of opioid and non-opioid users would 
be helpful, such as the age of those opioid users who seek treatment. The availability 
of these data should now allow this analysis (6). 
As explored in Section 2, the overarching question in comparing DRDs between countries or 
over time is whether or not the observed risk of DRD is different in different countries and 
whether or not that risk has changed. This requires both accurate knowledge about the 
number of DRDs that occur and knowledge about the size of the drug user population that is 
at risk, in order to estimate DRD rates. Alternatively, comparison might be on the basis of 
evidence derived from studies of DRD, and thus DRD rates, observed within drug user 
cohorts of known size. 
Recommendation: the rate of DRD per capita of the general population, although a 
helpful indicator of the population burden from DRDs, is not an adequate basis for 
comparisons of DRD risk among problem opioid users in different countries, or over 
time, because of underlying differences in POU prevalence rates and should not be 
used as such (see Boxes 2 and 5). 
As shown in Section 4, estimates of the size of the at-risk population are lacking and/or 
imprecise and there is no suitable evidence on which to base an assessment of changes in 
DRD risk over time. The EMCDDA currently (2016) publishes POU (now high-risk opioid 
user (HROU)) prevalence estimates for the majority of Member States, but these were 
available for only three of the seven countries considered in this work (and one of these 
estimates relates to a decade ago). In view of the interest in DRDs in these countries and 
the preponderance of opioid involvement in these deaths, the remaining countries should 
consider whether or not it is feasible for them to generate POU prevalence estimates. 
Countries that have produced POU estimates have, most commonly, based these on the 
CRC method, and recent work to account for bias in the application of this method has 
shown promising results (Jones et al., 2016). However, countries are not always consistent 
in the data sources used to support this approach; lack of consistency may have implications 
for the comparability of the estimates obtained. Countries’ capacities to apply CRC may be 
constrained by the availability of suitable data sources or the feasibility of case-linking these, 
in which case it may be necessary to employ other approaches, which may introduce further 
(6) For instance, see the Statistical Bulletin available from http://www.emcdda.europa.eu/data/stats2016 
(Treatment demand > Current situation > Age of treatment > Never previously treated > Heroin). 
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problems of comparability. The use of mortality data (i.e. overdose-related mortality rate in a 
cohort) as a basis for prevalence estimation, or the mortality multiplier estimation method, is 
inadvisable in the context of providing a denominator for DRDs. The DRD rate thus 
calculated would be the same as the overdose death rate of the cohort study. It is important 
to note that prevalence estimates will be subject to a degree of uncertainty and that where 
estimates are imprecise there may be difficulties in discerning differences between countries 
or over time. 
 
Recommendation: comparisons of the number of (opioid) DRDs should be 
considered in the context of estimates of POU prevalence. Countries that do not 
already do so should be encouraged to investigate the scope to produce such 
estimates, although their capacity to do so may be constrained by the availability of 
supporting data, national privacy regulations, etc. 
Cohort studies may provide an alternative, and potentially more precise, approach to 
comparing DRDs. However, only a very limited number of cohort studies that would provide 
a suitable basis for comparison among the seven countries is available. Researchers in 
several Member States, and elsewhere, have undertaken cohort studies of mortality that 
consider the rate of DRD in known drug user/POU cohorts (recent examples of European 
work include Clausen et al., 2009; Clausen et al., 2008; Merrall et al., 2012; Merrall et al., 
2013; Pierce et al., 2015; Pierce et al., 2016). The EMCDDA recommends that this approach 
should be a key component of understanding DRD and publishes guidelines for undertaking 
such work (EMCDDA, 2012c). Cohort studies can enable more precise analysis of DRD 
rates than may be achieved via comparison of population-level DRDs and prevalence 
estimates, because of the lack of precision in the latter. Most such studies have employed a 
case-linkage (otherwise referred to as a cross-registry) method, whereby cases present in 
both a known drug user cohort and official mortality records are linked. Thus, if the linkage is 
accurate, the number and rate of DRDs in the cohort can be enumerated and, if the cohort is 
representative, this provides an indication of DRD rates in the wider drug-using population. 
This approach has the advantage of being highly cost-effective and, if suitable cohorts are 
available, enables the assessment of mortality in large numbers of drug users. However, 
there can be difficulties in comparing the results of such studies. Many studies have 
considered mortality among treated drug users, often with the aim of comparing changes in 
DRD risk associated with treatment. However, there may be differences in DRD risk among 
treated, untreated and never-treated individuals, whereby risk is likely to differ according to 
treatment status but is not always reported according to such (see Box 6 for a related 
example of the difficulty of comparing recent studies from Norway and Scotland). Several 
factors should be considered when assessing the comparability of such studies; for example: 
• Are case definitions for cohort membership clearly defined and are cohorts drawn 
from the same underlying population? A study of DRDs among problem opioid users 
is not comparable with a study among ‘drug users’ or even, necessarily, a study 
among ‘treated drug users’. 
• Related to the above, is the underlying population representative of those at risk of 
DRD? A study of DRDs among a cohort that uses a range of drugs is likely to 
produce a lower estimate of DRD risk than a study specifically among problem opioid 
users. 
• Do studies use the same definition of DRD? 
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• Are cohorts accrued from the same setting? A cohort drawn from criminal justice 
settings may have a different DRD risk than a cohort drawn from treatment settings. 
In addition, the type of treatment available in one country may confer more or less 
risk than that in another. 
• Does analysis adjust for changing treatment status and/or report in-/out-of-treatment 
risk separately? Unmeasured heterogeneity in treatment enrolment during 
observation may confound comparison. 
• Does analysis adjust for risk factors such as age or drug use behaviours? Adjusted 
risk in one study may not be comparable with unadjusted risk in another. 
• Do the studies relate to contemporary time periods? Risk may vary by epoch, 
confounding comparison of studies from different periods. 
• Are DRD or all-cause mortality rates reported? Many studies have reported all-cause 
mortality rates, for which the rate is expected to be very much higher (note that 16 of 
the 23 drug user mortality cohort studies considered here (Box 6) did not report a 
DRD rate). 
• Are recruitment and observation periods coterminous and are the latter sufficiently 
short to allow reasonable certainty that the individuals in the cohort remained active 
drug users? Very long-term follow-up of drug user cohorts, although informative, may 
fail to account for reductions in risk associated with drug-use cessation as time 
elapses. 
 
To date, many European studies have varied with respect to all of these factors, illustrating 
the difficulty of making comparisons between them. Note that it is more straightforward to 
assess comparability where studies adhere to the STROBE (Strengthening the Reporting of 
Observational Studies in Epidemiology) checklist of items, which should be included in 
reporting cohort studies (7). The EMCDDA previously provided guidance on ensuring 
comparability between cohort studies (Perucci et al., 1999a; Perucci et al., 1999b) and noted 
the difficulty of making comparisons based on published findings alone (EMCDDA, 1997). 
Moreover, the EMCDDA has highlighted the importance of accurate case linkage and that it 
may be difficult, in some countries, to identify causes of death (EMCDDA, 2015). 
 
Recommendation: countries should be encouraged to investigate the scope of 
assessing rates of DRD among known cohorts of problem opioid users, using 
methods that are comparable between countries and over time. There is a need for 
further cohort studies and updates to the currently available studies. The central 
coordination of such studies, through joint protocols (EMCDDA, 2012c; EMCDDA, 
2015), is beneficial to improving comparability. 
 
 
(7) http://www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_cohort.pdf 
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Appendices: Country-level summaries 
Data discussed and presented in the country summaries (below) are primarily derived from 
the EMCDDA country profiles (available from http://www.emcdda.europa.eu/countries), 
unless otherwise specified. Country profiles are populated by data submitted by each 
national focal point within workbooks related to different aspects of drug use, e.g. harm and 
treatment. The workbooks are more complete documents reported to the EMCDDA as part 
of annual national reporting to complete the standard figures reported for the Statistical 
Bulletin (available from http://www.emcdda.europa.eu/data/stats2016). Although not 
available on the EMCDDA website, these workbooks may be provided on request.   
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Appendix 1: Denmark 
Sources of data on overdose 
The numbers of drug-induced deaths (DIDs) in Denmark are recorded in two registers — the 
National Police Register and the State Serum Institute’s Cause of Death Register (the 
GMR). Information provided by the GMR indicates that 94-100 % of DIDs in Denmark have 
known toxicology between 2006 and 2013, but levels have continually decreased over the 
time series. Both the National Police Register and the GMR show similar trends, which 
suggest that recording issues are unlikely to explain why rates are ‘high’. 
 
Background epidemiology 
Estimates of ‘problem drug users’ 
Trends in the number of ‘drug abusers’ (i.e. people who use drugs (PWUD)) in Denmark 
appear to have increased over time, with the most recent estimate suggesting there were 
33 000 PWUD in Denmark in 2009. However, these figures include cannabis users (11 000 
in 2009); no specific estimate of the number of POUs exists (Sundhedsstyrelsen, 2014). In 
2009, there were an estimated 13 000 PWID in Denmark; most Danish PWID are opioid 
users and 50-67 % are unknown to treatment services (Sundhedsstyrelsen, 2014). 
Drug-related infectious diseases 
It is estimated that up to 75 % of PWID in Denmark are infected with HCV and 35 % are 
infected with hepatitis B virus (HBV) (Sundhedsstyrelsen, 2014). Fewer than 5 % of PWID 
are infected with HIV and between 2005 and 2014 PWID accounted for 4-11 % of newly 
diagnosed HIV cases in Denmark (Sundhedsstyrelsen, 2014). It should be noted that 
infectious diseases related to drug use are likely to be underdiagnosed in Denmark, since a 
large proportion of PWID are not regularly tested. 
Drug treatment data 
There appears to have been a general decline, between 2005 and 2011, in the proportion of 
PWUD treated for the first time, with opioids being reported as the main problem, decreasing 
from 17 % to 5 %. At the same time, the proportion of people who inject heroin in this 
population increased between 2005 and 2008, and then decreased over the next two years 
before rising again to its highest level (27 %) in 2011. Although contrasting, these trends are 
perceived to reflect a general decrease in opioid use within the Danish population over time 
and increasing engagement in treatment among older people who inject heroin. No drug 
treatment data are available for after 2011. 
Opioid substitution treatment 
In 2013, more than 7 000 individuals received OST — either with methadone (6 200; 89 %) 
or buprenorphine. This potentially translates to ~ 54 % of PWID based on 2009 estimates 
(i.e. 13,000), although it is possible this denominator has changed (i.e. decreased) since 
2009 when looking at changes in the proportion of new opioid users recorded in the 
treatment data. Just over 500 (7%) of those on OST in 2013 were in prison or on probation. 
The overall OST number is down from the estimates from 2010 (7,850; 60%) and 2011 
(7,600; 58%). 
Non-fatal poisoning 
Hospital contacts with drug poisoning as the ‘action’ diagnosis are recorded in the National 
Patient Register (LPR). It is notable that there was a decrease in the number of recent 
poisonings related to heroin between 2010 and 2014 (from 195 in 2010 to 107 in 2014) 
(Figure A.1.1), a trend that mirrors the corresponding increase in OST engagement and the 
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increase in the proportion of injecting heroin users accessing treatment for the first time. In 
contrast, poisonings related to other opioids increased sharply over the time series. This is 
largely attributed to an increase in the use of prescription opioids within Denmark in recent 
years. The data retrieval criterion changed in 2010, making comparisons before and after 
this period difficult; it is likely that poisonings before 2010 were under-reported. 
Figure A.1.1: Hospital contacts resulting from intoxication and poisoning by main drug, Denmark 
2005-2014 (source: the National Patient Register) 
 
Heroin assisted treatment 
As of March 2009, treatment with medically prescribed heroin for injection has been allowed 
in Denmark, with five clinics established. The number of patients engaged with HAT 
programmes is limited each year by funding, but had risen to 300 by 2013. 
 
Drug consumption rooms 
Drug consumption rooms (DCRs) were legally authorised in Denmark in 2012, with three 
DCRs now established across the country. Although originally established to address the 
opioid-injecting epidemic, DCRs in Denmark are now increasingly used by individuals 
injecting crack cocaine. 
 
Take-home naloxone 
Based on positive outcomes from a pilot project in the Copenhagen Municipality, an 
intranasal THN project financed by the state was initiated in January 2013, based in four 
municipalities. As of October 2014, 100 people had been trained to train others, and 121 
drug users had received overdose prevention training and THN kits. There have been seven 
instances of reported naloxone use for overdose reversal. 
Injecting equipment provision 
A study by Local Government Denmark concluded that the number of PWID with access to 
clean needles and syringes is ‘high’, although the coverage rate of syringe exchange in 
Denmark has never been quantified. 
Drug-induced deaths: overall 
In Denmark, the number of annual DIDs increased from 227 in 2006 to 235 in 2013, an 
increase of 4 % (Figure A.1.2). By era, DIDs averaged 254 per annum between 2006 and 
2009, rising slightly to almost 260 per annum in the most recent four-year period for which 
data are available (2010-2013). A visual inspection of the data suggests that the overall 
number of DIDs increased gradually over the time series to a peak in 2011, with decreases 
observed in the following two years. However, it is too early to confirm if the recent decline 
represents definitive epidemiological evidence of a falling trend. 
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Figure A.1.2: Crude numbers of annual drug-induced deaths recorded in Denmark, 2006-2013 
(source: National Focal point report to the EMCDDA through Standard Table 6) 
 
 
The overall proportion of DIDs in Denmark accounted for by males has remained relatively 
stable at between 70 % and 78 % across the time series. The average (mean) age of those 
affected has increased over the time series, from 42.8 years between 2006 and 2009 to 45.6 
years between 2010 and 2013. Between-era differences in DIDs across different age groups 
also show some evidence of change. For example, deaths in older adults all appear to have 
increased significantly regardless of how the data are categorised (> 35 years, p = 0.0002; 
> 45 years, p = 0.0001; > 55 years, p = 0.0001). Similarly, the proportion of deaths in the 
younger adult group (< 35 years) decreased significantly (p = 0.0001). 
Drug-induced deaths: toxicology 
The number of cases recorded involving opioids increased from 181 in 2006 to 191 in 2013, 
an increase of 6 % (Figure A.1.2). Opioid-related DIDs averaged 202 per annum between 
2006 and 2009, rising to over 214 per annum in the most recent four-year period for which 
data are available (2010-2013). When comparing the presence of opioids in DID toxicology 
between eras, the data show a significant increase between the 2006-2009 (81 %) and 
2010-2013 (85 %) periods (p = 0.01). A visual inspection of the data shows patterns similar 
to those for the overall number of DIDs; the overall numbers have increased steadily over 
the time series to a peak in 2011, with decreases observed in the following two years. 
Parallel patterns are perhaps to be expected given that opioid-related DIDs account for over 
80 % of all DIDs in Denmark. 
Based on National Police Register data, on average three to four drugs are found upon 
examination of all DIDs in Denmark, which is indicative of polydrug use as major contributor 
to drug-related mortality. Of the 263 deaths recorded in the National Police Register in 2014, 
191 (73 %) were caused by poisoning from one or several drugs. 
Summary 
Although no recent prevalence data exist to confirm such a hypothesis, it appears that the 
scale of heroin injecting has decreased since 2009, based on treatment data and national 
focal point communication. It is possible that the decreasing prevalence of heroin injecting 
and changing drug use patterns more generally in Denmark are having some impact on 
mortality rates among PWUD. Polydrug use remains a key contributor too, although the 
composition of polydrug combinations could be changing and also having an impact on 
death rates. 
The average age at DID in Denmark has been rising for many years, as it has elsewhere in 
Europe, and parallels the increase in age among traditional opioid (i.e. heroin) user cohorts. 
The average age at DID in Denmark is among the highest in Europe and possibly reflects a 
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combination of improving treatment and care for PWUD and a decrease in the onset of 
newly injecting opioid users. 
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Appendix 2: Estonia 
Sources of data on overdose 
The National Cause of Death Register (the GMR — Estonian Causes of Death Registry) and 
the Estonian Forensic Science Institute provide data on DIDs in Estonia. There have been 
no notable methodological changes over time in relation to the source of data (the GMR), 
case definition (Selection B: ICD-10) or geography. Information provided by the GMR 
indicates that DIDs in Estonia had between 97 and 100 % coverage of known toxicology. 
Background epidemiology 
Estimates of ‘problem drug users’ 
There were an estimated 13 886 (95 % CI 8 132-34 443) PWID in Estonia in 2004, which 
equates to a prevalence figure of 2.4 % (95 % CI 1.4-5.9 %) among people aged 15-44 
years ('Uusküla' et al., 2007; 'Uusküla' et al., 2013. The estimated prevalence of PWID 
among the population aged 15-44 years increased to 15 675 (2.7 %; 95 % CI 1.8-7.9 %) in 
2005, but then declined to 11 493 in 2008 (2.0 %; 95 % CI 1.4-5.0 %) and 5 362 in 2009 
(0.9 %; 95 % CI 0.7-1.7 %). At best, this corresponds to a significant decrease in the PWID 
population of 56 % over the study period, 2004-2009. However, taking into account the wide 
CIs, the overall decrease may actually have been much smaller and results should therefore 
be interpreted with caution. Although no definitive explanation exists with regard to why the 
prevalence of PWID in Estonia may have decreased between 2005 and 2009, the reduction 
is consistent with cross-sectional studies that show significant reductions in the number of 
new injectors recruited over the study period (Uusküla et al., 2011). 
Drug-related infectious diseases 
HCV antibody prevalence among PWID ranges from 76 % in the Narva region (2010) to 
90 % in Tallinn (2013). Hepatitis B surface antigen (HBsAg) prevalence ranges from 3 % to 
22 %. The Joint United Nations Programme on HIV/AIDS (UNAIDS) reports that the 
prevalence of HIV among PWID in Estonia has fallen in recent years, from 62.5 % in 2009 to 
52.4 % in 2012 (UNAIDS, 2012). Trend data from the National Institute for Health 
Development (NIHD) indicates that the number of newly diagnosed cases of HIV among 
PWID has fallen considerably since data collection began, from around 100 in 2009 to 21 in 
2014 (Figure A.2.1). This fall is in line with decreasing trends in the overall number of new 
diagnoses of HIV in the Estonian population. 
Drug treatment data 
The proportion of total clients in the treatment system reporting opioids as the main drugs 
used has fallen marginally across the time series, from around 98 % in 2008 to 90 % in 
2014, but remains very high in comparison with all other substances. The majority of clients 
report illicit fentanyl as their primary drug, as they have done for a number of years. 
However, given that there are no specific treatments or treatment centres funded for users of 
other substances, it is possible that treatment demand indicator (TDI) data are skewed 
towards opioid use and underestimate treatment need/demand for users of other drugs. The 
majority (70 %) of clients have injected at some point in the past and only 5 % claimed to 
have never injected any drugs, thus implying that PWID prevalence estimates provide a 
reasonable proxy for POU prevalence. 
In 2012 and 2014, the National Drug Treatment Database had technical issues that resulted 
in the loss of approximately 30-40 % of treatment records. TDI data for those years should 
therefore be interpreted with caution. 
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Opioid substitution treatment 
In 2014, there were seven substitution treatment providers in Estonia and 919 clients were 
receiving substitution treatment. Outpatient treatment centres have mainly provided OST 
with methadone since 2001 (in prisons since 2008). Buprenorphine treatment is provided by 
only one hospital at a cost to the patient, while methadone treatment is free. Based on data 
from the National Drug Treatment Database, only 2 % of OST clients received 
buprenorphine in 2014. From 2009 to 2013, the number of OST clients increased gradually 
but decreased in 2014 (Figure A.2.1). Assuming the prevalence of PWID is representative of 
POU prevalence, it is estimated that between 9 and 19 % of PWID were engaged in OST 
between 2008 and 2009. Again, CIs are wide and results should be interpreted with caution. 
 
Figure A.2.1: Number of clients in OST, 2007-2014 (source: National Focal point report to the 
EMCDDA through Standard Table 24) 
 
 
Injecting equipment provision 
The number of syringes distributed to PWID in Estonia increased markedly between 2003 
and 2010, but has stabilised since at around 200 000 per year. Using the 2009 estimate of 
5 000 PWID, this is equivalent to around 40 syringes per year per problem opioid user. 
 
Take-home naloxone 
In September 2013, a THN pilot programme was launched in Estonia by the NIHD. In total, 
1 135 participants received training and 1 130 naloxone kits were disseminated during the 
period of September 2013-August 2015. The majority of kits were distributed to PWID (920;, 
81 %). During the same period, 251 repeat naloxone prescriptions were reported, which 
provides an indication of the level of naloxone use within the community. These data 
suggest that, in Estonia, the number of THN kits issued was almost nine times the number of 
opioid-related deaths. 
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Drug-induced deaths: overall 
Figure A.2.2: Crude number of annual drug-induced deaths recorded in Estonia, 2008-2014 (source: 
National Focal point report to the EMCDDA through Standard Table 6) 
 
 
In Estonia, the annual number of DIDs increased from 67 in 2008 to 170 in 2012, an 
increase of 154 %. In the two following years, the numbers decreased considerably, to 111 
(2013) and 98 (2014) (Figure A2.2). However, it is too early to confirm if this recent decline 
represents definitive epidemiological evidence of a falling trend. 
The overall proportion of DIDs in Estonia accounted for by males has remained relatively 
stable, at between 84 % and 90 % across the time series. The average (mean) age at DID in 
Estonia increased from 31.1 years in 2012 to 31.9 years in 2013 and 33.4 years in 2014. 
Moreover, the proportion of deaths occurring in those aged under 30 years decreased from 
45 % in 2012 to 28 % in 2014. 
Drug-induced deaths: toxicology 
Opioid-related DIDs accounted for over 90 % of all DIDs in Estonia between 2012 and 2014, 
the vast majority of which involved illicit fentanyl use. However, the number of DIDs for which 
opioids were recorded in toxicology decreased from 165 in 2012 to 98 in 2014, a decrease of 
41 % (Figure A.2.2). Poisoning involving fentanyl is frequently combined with amphetamines 
(Tuusov et al., 2013). 
Purity 
Since 2012, the purity of fentanyl has decreased in Estonia, coinciding with a decrease in 
DIDs in Estonia over the same period. The decrease in the purity of fentanyl in Estonia has 
been associated with police operations targeting street vendors (Abel-Ello et al., 2014). 
However, fentanyl is extremely potent by weight; therefore, small variations in the illicit 
production or processing of the drug may lead to large variations in effective dosage, 
increasing the likelihood of overdose (Uusküla et al., 2013). 
Summary 
Studies suggest that the number of PWID/problem opioid users in Estonia may have 
declined to some extent between 2005 and 2009; however, DIDs continued to increase until 
a peak in 2012, then decreased thereafter. Local intelligence attributes this decrease in DIDs 
to a combination of decreasing PWID/POU prevalence and the implementation of a THN 
programme. The former is not yet supported by a prevalence study using similar methods to 
those conducted earlier. However, it is plausible to assume that those who remained within 
the PWID cohort post 2009 were at increased risk of DID, as the purity of fentanyl continued 
to increase (until 2012) and then decreased across the time series. 
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The naloxone project is likely to have already affected the opioid-related death rate and will 
continue to do so in subsequent years if it is maintained at current levels. However, the 
overall DID rate in Estonia has been falling since 2012 and the initial decrease cannot 
therefore be attributed to naloxone alone. Alternative explanations for the decline DIDs in 
Estonia could be that the scale-up of harm-reduction and treatment services reached a 
sufficient level to affect overall mortality. It is true that coverage of needle exchange and 
OST provision increased across the time series, although not to a level at which such a 
direct impact on DIDs would be expected. 
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Appendix 3: Finland 
Sources of data on overdose 
The National Cause of Death Register (GMR — Statistics Finland) and the Special Registry 
provide data on DIDs in Finland. There have been no notable methodological changes over 
time in relation to the source of data (GMR), case definition (Selection B: ICD-10) or 
geography. Information provided by the GMR indicates that DIDs in Finland have 100 % 
coverage of known toxicology. 
Background epidemiology 
Estimates of ‘problem drug users’ 
The latest estimates of ‘problem drug use’ are from 2012 and indicate that the ‘opioid abuse’ 
estimate is between 13 000 and 15 000, or 0.38-0.45 % of the population (Ollgren et al., 
2014). The opioid most commonly used in Finland is buprenorphine (Forsell and Nurmi, 
2013). 
Drug-related infectious diseases 
By the end of 2014, the National Infectious Diseases Register estimated HIV prevalence 
among PWID to be 1.2 % and HCV prevalence to be 74 % (8). The numbers of new HIV and 
HCV cases have remained largely stable for the past 10 years at around 150 and 1 200 per 
annum, respectively, as has the proportion accounted for by PWID (approximately 5 % (for 
HIV) and 50 % (for HCV) of all new diagnoses). 
Drug treatment data 
The Finnish drug treatment data collection, which provides the TDI data, is a voluntary data 
collection system. In 2014, over half (53 %) of all drug clients in the Finnish drug treatment 
data collection system reported opioids as their primary drug, primarily buprenorphine (85 % 
of all opioids). Of the remainder, the most notable drugs reported were stimulants (15 %) 
and cannabis (14 %). Two thirds of clients are male, and the median age is 30 years. 
 
The most notable trend in the Finnish TDI data is the increasing amount of opioid users, in 
particular the increasing use of buprenorphine. Available data and local intelligence on 
service delivery changes indicate that the increase of opioid-related presentations (for new 
and all clients) is a result of both an increase in the prevalence of opioid use in Finland over 
the time series and service reconfiguration that focuses treatment much more on those with 
problem opioid use. 
 
The primary use of buprenorphine by treatment entrants has persisted since 2002. The 
proportion of individuals presenting to treatment with primary heroin use have fallen 
dramatically since 2001, to fewer than 5 % of the total opioid-using group in 2014. There is 
some evidence of an increase in ‘other’ opioids being reported between 2004 and 2013, to 
around 30 % of all primary opioid presentations, but with a sharp drop in 2014. Other opioids 
reported include a broad range of codeine, oxycodone, fentanyl and tramadol, although 
individually all are at levels comparable to heroin, i.e. less than 5 %. 
Opioid substitution treatment 
Trends in the numbers of clients in OST in Finland have increased in the past 15 years to a 
peak of 3 000 clients in 2014 (Figure A.3.1). Based on the most recent prevalence 
estimates, this would suggest that between 20 % and 23 % of Finnish opioid users were 
(8) Anonymous and voluntary finger prick blood sampling linked with a risk behaviour questionnaire. Participation was an option offered to 
all clients entering needle exchange during the period of 1.3.2014-31.6.2014. 
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engaged in OST in 2014. Almost two thirds (62 %) of those on OST in 2011 were on 
buprenorphine-based therapy (Selin et al., 2015). However, in the same year, fewer than 
3 % of prisoners were on OST, a trend which has persisted (9). 
 
Figure A.3.1: Trends in the numbers of clients in OST, 2003-2012 (source: National Focal point report 
to the EMCDDA through Standard Table 24) 
 
 
Finland uses CRC methods to estimate POU, but differs from other European countries with 
regard to the data sources it uses to produce its CRC estimate. Therefore, the treatment 
coverage estimate of approximately 20 % is not likely to accurately reflect the scale of 
treatment coverage among opioid users (i.e. those on OST). 
Injecting equipment provision 
The IEP coverage in the community is estimated to be 100 %. To date, there are still no IEP 
facilities available within Finnish prisons. In recent years, the number of clients using the 
NSP at community facilities has stabilised at between 11 000 and 14 000. 
Drug-induced deaths: overall 
In Finland, the number of DIDs rose from 126 in 2005 to 176 in 2014, an increase of 40 % 
(Figure A.3.2). By era, DIDs averaged 150 per annum between 2005 and 2009, rising to 
almost 190 per annum in the most recent five-year period for which data are available (2010-
2014). A visual inspection of the data suggests that the overall number of DIDs increased 
steadily over the time series to a peak in 2012, with decreases observed in the following two 
years. However, it is too early to confirm if the recent decline represents definitive 
epidemiological evidence of a falling trend. 
 
Figure A.3.2: Crude numbers of annual drug-induced deaths recorded in Finland, 2005-2014 
(9) Martta Forsell, personal communication.  
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The overall proportion of DIDs in Finland accounted for by males has remained relatively 
stable, at between 74 % and 81 % across the time series. The average (mean) age of those 
affected has also remained relatively stable: 38.2 years between 2005 and 2009, and 37.8 
years between 2010 and 2014. In comparison, data from the Special Registry indicate that 
the mean age of DIDs is rising in line with other European countries. The differences 
between the SMR and GMR mean age trends are likely to be explained by the inclusion in 
the GMR data of older adult deaths coded as ‘drug poisoning’ but with no history of drug 
misuse. 
Drug-induced deaths: toxicology 
The number of deaths with opioids recorded in the toxicology increased from 100 in 2005 to 
146 in 2014, an increase of 46 % (Figure A.3.2). Opioid-related DIDs averaged 125 per 
annum between 2005 and 2009, rising to over 150 per annum in the most recent five-year 
period for which data are available (2010-2014). A visual inspection of the data shows 
patterns similar to those for the overall number of DIDs. Parallel patterns are perhaps to be 
expected given that opioid-related DIDs account for over 80 % of all DIDs in Finland. 
Overall, the majority (over 80 %) of DID cases involve multiple drugs, with few attributed to 
poisoning as a result of consumption of a single drug (10).There has been little change in the 
trend of polydrug involvement in DIDs in Finland over time, with multiple drugs recorded for 
between 81 % and 92 % of all cases between 2008 and 2014. 
Summary 
The number of DIDs recorded in Finland increased steadily between 2005 and 2014, 
although early indications suggest that this rising trend peaked in 2012. Each of the different 
data sources on DIDs in Finland broadly shows an upwards trend across the time series with 
minor variations, which suggests that the increase is not an artefact of data recording. The 
absence of robust prevalence data on problem drug use, in particular opioid use, limits the 
ability to draw any meaningful conclusions as regards the drivers of this increase, for 
example whether the increase in DIDs reflects an increase in the number of individuals using 
drugs or is due to an increased risk of DID among this population. However, increases in the 
number of opioid-related DIDs and in clients engaged in OST could point towards an overall 
increase in prevalence. 
(10) Pirkko Krikku, Forensic toxicologist, Finland National Institute for Health and Welfare, personal communication, 30 August 2016. 
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Appendix 4: Ireland 
Sources of data on overdose 
DID cases in Ireland are analysed using data from a special register: the National Drug-
Related Death Index (NDRDI). The data submitted to the EMCDDA for ‘Selection D’ are 
effectively a subset of the NDRDI data. Prior to 1998, data submitted to the EMCDDA were 
only from the GMR using Selection B. Data from the NDRDI are based on forensic 
toxicological examinations carried out at the request of the pathologist or coroner. Coverage 
with regard to known toxicology in DID cases is generally very high unless samples are not 
viable, which is rare. 
Background epidemiology 
Estimates of ‘problem drug users’ 
In 2006, a CRC study estimated a total number of 20 790 opioid users (range: 18 136-
23 576), or 7.2 per 1 000 population aged 15-64 (range: 6.2-8.10 per 1 000) (Kelly et al., 
2009). A new estimate of the number of opioid users in Ireland is expected to be published 
soon. 
Drug-related infectious diseases 
The long-term trend shows decreasing numbers of new HIV diagnoses among PWID in 
Ireland, from over 100 in 1986 to just over 20 in 2014 (Department of Health by National 
Disease Surveillance Centre and HPSC, 2015). However, there has been an increase in 
new HIV diagnoses among PWID since 2013 linked to the injection of a synthetic cathinone 
(Giese et al., 2015). There has been a downwards trend in HCV infection notifications since 
peak numbers (1 541) were recorded in 2007. Around 60 % of cases have reported risk 
factor data between 2010 and 2014; PWID make up the majority of these cases, although 
there are indications that the proportion of cases they account for is beginning to decrease. 
Among acute cases of HBV in 2014, none was from the PWID population. 
Drug treatment data 
Data on drug treatment in Ireland are collected through two national data collection tools: the 
Central Treatment List (CTL) and the National Drug Treatment Reporting System (NDTRS). 
It is not possible to estimate the total number of clients in the national network, as there is no 
information on centres that do not report to the EMCDDA’s TDI. Coverage of the NDTRS, 
through which the TDI data are reported, has remained consistently high, at over 70 %. 
However, as there is no national unique health identifier, duplication can be controlled for 
only within treatment centres, not at national level. Therefore, a person may be counted 
more than once if they attend more than one treatment centre within the same calendar 
year. 
 
In 2014, opioids, mainly heroin, were the main problem drug used by entrants to treatment. 
Despite this, the proportion of opioid cases has decreased year on year over the past 11 
years, from 65 % in 2004 to 50 % in 2014. 
Opioid substitution treatment 
Almost all OST provided is methadone. Buprenorphine in combination preparations is not 
routinely available in Ireland and fewer than 1 % of clients receive it. The number of clients 
registered for OST on 31 December each year reported by the CTL increased from 3 689 in 
1998 to 9 764 in 2014. This increase can be explained by the inception of the service in 
1998, with more clients entering treatment and more facilities becoming available year on 
year (Farrell and Barry, 2010). Fewer than 5 % receive OST in prison. Based on available 
prevalence estimates, approximately 40 % of problem opioid users were engaged in OST in 
2006. 
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Figure A.4.1: Trends in the number of clients in OST, Ireland, 1998-2014 (source: National Focal point report 
to the EMCDDA through Standard Table 24) 
 
Injecting equipment provision 
Needle and syringe exchange services were first provided in Ireland in 1989, when five 
exchanges were established. There are now over 100 exchanges in operation across three 
models of service (‘Static’, ‘Outreach’ and ‘Pharmacy’). Since the pharmacy-based needle 
exchange programme was established in October 2011, the number of pharmacies providing 
needle exchange has increased, from 42 at the end of 2011 to 99 by the end of 2013. The 
number of people attending these services also increased from, on average, 306 per month 
in 2012 to 933 per month in 2013. 
Take-home naloxone 
A naloxone demonstration project is currently under way. Findings from the initial evaluation 
indicate that almost 600 people were trained in the use of naloxone and in recognising and 
effectively managing overdose events (Clarke and Eustace, 2016). In addition, 95 naloxone 
prescriptions were issued and five administrations reported, four of which were by front-line 
drug workers and one was administered peer to peer. 
Drug-induced deaths: overall 
Figure A.4.2: crude number of annual drug-induced deaths recorded in Ireland, 2004-2013 (source: 
National Focal point report to the EMCDDA through Standard Table 6) 
 
 
In Ireland, the annual number of DIDs increased from 127 in 2004 to 219 in 2013, an 
increase of 72 % (Figure A.4.2). By era, DIDs averaged 181 per annum between 2004 and 
2008, rising to 206 per annum in the most recent five-year period for which data are 
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available (2009-2013). A visual inspection of the data suggests that the overall numbers of 
DIDs increased consistently between 2004 and 2009, but have fluctuated since then. 
 
The overall proportion of DIDs in Ireland accounted for by males has remained relatively 
stable, at between 73 % and 81 % across the time series. The average (mean) age of those 
affected by DID in Ireland has increased over time, from 32.6 years between 2004 and 2008 
to 35.5 years between 2009 and 2013. This ageing cohort effect is reflected in between-era 
differences in DIDs across all age groups, with significant increases and decreases among 
all categories (under 25 years, p = 0.01; under 35, p = 0.01; over 35, p = 0.01; over 45, 
p = 0.04; and over 55, p < 0.01). NDRDI data highlight that, in females, the age (median age 
range: 42-49 years) at poisoning-related death is, on average, consistently higher than in 
males (median age range: 34-38 years) across the time series. 
Drug-induced deaths: toxicology 
Toxicology data are available for between 78 and 96 % of DIDs over the time series. Where 
known, the number of deaths with opioids recorded in the toxicology increased from 121 in 
2004 to 187 in 2013, an increase of 55 %. Opioid-related DIDs averaged 133 per annum 
between 2004 and 2008, rising to over 160 per annum in the most recent five-year period for 
which data are available (2009-2013). A visual inspection of the data shows patterns for 
opioid-related deaths similar to the overall number of DIDs; the overall numbers have 
increased steadily over the time series to 2009, with fluctuations observed in the following 
years. Parallel patterns are perhaps to be expected given that opioid-related DIDs account 
for over 85 % of all DIDs with a known toxicology in Ireland. 
 
According to NDRDI data, the majority of poisoning deaths between 2004 and 2013 involved 
more than one drug, with an increasing trend for polydrug-related poisoning deaths evident 
across the time series. Data from the NDRDI also show that methadone (alone or with 
another drug) continues to be the opioid most commonly implicated in poisoning deaths. In 
2013, methadone was implicated in 93 deaths, accounting for one in four (24 %) of all 
deaths recorded in the NDRDI database that year. The overall trend indicates a rise in 
methadone involvement in DIDs, from 15 % in 2004 to a peak of 31 % in 2011, when there 
were 119 deaths in which methadone was implicated. Between eras, polydrug use 
involvement in methadone-implicated deaths was significantly higher in the most recent five-
year period for which data are available (2009-2013; 89.1 %) than in an earlier period (2004-
2008; 76.1 %) (p < 0.01). It is also interesting to note that the proportion of cases in which 
methadone was implicated and in which methadone was being prescribed at time of death 
was highest between 2006 and 2009 (47-59 %), but has decreased in recent years, 
suggesting that diversion may be increasing. 
 
In 2013, heroin was implicated in 86 deaths, accounting for one in five (22 %) of all deaths 
that year. This represents the first increase in heroin-related deaths since 2009. Again, 
heroin was rarely the only drug involved, with polydrug use a prominent feature of 
poisonings in which heroin was implicated between 2004 and 2013. Benzodiazepines were 
the main drugs implicated along with heroin. 
Suicides 
The total number of suicides recorded in Ireland has fallen in recent years, from a peak of 
554 in 2011 to 451 in 2015. Taking account of population size, the rate of suicide per 
100 000 people has decreased markedly across the time series, from a peak of 13.5 per 
100 000 in 2001 to 9.7 per 100 000 in 2015. 
Purity 
No routinely collected data series on drug purity levels in Ireland exists. However, specific 
studies have been undertaken to investigate drug purity levels, notably the work of Boyle et 
al. (2014). In the analysis undertaken by Boyle et al., in a sample of 239 diamorphine 
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(heroin) cases, the mean purity was 47 % in 2010, 30 % in 2011 and 24 % in the first three 
months of 2012. The study revealed ‘a general decline of diamorphine purity over the time 
period, with the 2012 average being nearly half the average purity obtained for 2010’. 
Summary 
The number of DIDs in Ireland increased steadily between 2004 and 2009, but has 
fluctuated in the years since. The absence of recent and consistent prevalence data on 
PDU, in particular opioid use, limits the ability to draw any meaningful conclusions as 
regards the drivers of these trends, for example whether the increase in DID reflects an 
increase in the number of individuals using drugs or is due to an increased risk of DID 
among this population. 
 
Basic statistical testing confirms evidence of an ageing cohort, with significant decreases in 
the proportion of DIDs in younger age groups (i.e. under 35 years) and increases in the 
proportion of older drug users (i.e. aged 35 years and above). This evidence of an ageing 
cohort is further confirmed by BBV infection and treatment data. The presence of heroin in 
toxicological and treatment data has diminished since 2009, coinciding with the heroin 
drought of 2010 and its associated impact on purity and availability. However, there are 
signs that the legacy of this drought is weakening, with the most recent data suggesting that 
the involvement of heroin in DIDs has risen for the first time since 2009 after the period of 
declining involvement. In contrast, the involvement of methadone in DIDs has increased in 
parallel with an increase in the number of individuals engaged with OST. Polydrug use also 
remains a key factor, with opioids rarely implicated on their own. 
 
Although absolute numbers of opioid-related DIDs have increased across the time series, 
the overall proportion they account for has decreased. This, coupled with increasing 
numbers in OST and decreases in the numbers of young people accessing treatment, 
suggests that the prevalence of POU may not have actually increased in recent years and 
that increasing DID rates may indeed reflect the increased risk among certain populations, 
e.g. older drug users, especially females. 
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Appendix 5: Norway 
Sources of data on overdose 
Data are sourced from the GMR and compiled by Statistics Norway. The GMR includes only 
Norwegian residents; however, asylum seekers with a six-month residence permit can be 
included. Double counting is controlled for and there are no estimated levels of under-
reporting in the dataset. Toxicological information is sourced from the Special Mortality 
Registry (SMR). This includes only substances that are listed as a cause of death. The 
autopsy rate for DRDs is consistently high over time, hence reported figures are, in the 
majority cases, based on toxicological confirmations of the DRDs. 
Background epidemiology 
Estimates of ‘problem drug users’ 
The most recent available estimates obtained by means of a treatment multiplier method 
suggest that around 9 015 high-risk opioid users (HROUs) were not in OST (95 % CI 6 708-
13 977) in 2013 (Waal et al., 2015), corresponding to a rate of 2.68 per 1 000 inhabitants 
aged 15-64 years (95 % CI 1.99-4.15 per 1 000 inhabitants). In the same year, there were 
approximately 7 000 clients in OST. However, it is not possible to combine these estimates 
to produce an overall number of problem opioid users because of inconsistencies in the 
methodologies between the two estimates. 
 
The estimates of the numbers of PWID are also based on a mortality multiplier method. It 
was estimated that, in 2013, there were 8 145 PWID (95 % CI 6 984-9 842) in Norway, 
which is a slight decrease from the 2012 figure of 8 400 (95 % CI 7 200-10 100). The 
number of PWID in Norway increased until 2001, after which it declined until 2003 and 
thereafter appeared to remain stable until 2008 (Figure A.5.1). The rate of injecting drug use 
in Norway decreased from 3.22 per 1 000 population in 2008 to 2.42 per 1 000 in 2012. The 
PWID population in Norway comprises mainly people who inject opioids and 
methamphetamine. 
Drug-related infectious diseases 
Few BBV prevalence studies among PWID in Norway have been carried out to date. In Oslo, 
annual prevalence studies were carried out in the 2002-2012 period among PWID attending 
low-threshold services and injection rooms. The 2012 survey showed that 62 % of PWID 
tested had had a hepatitis A infection or had been vaccinated against the disease, 35 % had 
had an HBV infection and 64 % had had an HCV infection. 
Among registered OST patients, the annual status survey for 2014 shows that 62 % of the 
clients whose status was known were HCV antibody positive, similar to 2013 (63 %) (Waal et 
al., 2015). This is lower than expected and is likely to be explained by the high proportion of 
cases with an unknown status (16 %). Furthermore, 2.4 % of the clients whose status was 
known were HIV antibody positive. Of the 249 new cases of HIV infection reported in 2014, 
only seven cases occurred among PWID. The number of HIV cases among PWID has 
remained at a stable and low level for many years.  
Drug treatment data 
The data source for treatment figures is the National Patient Registry (NPR). In 2014, the 
majority (43 %) of those in treatment had problems related to the use of opioids as their 
primary diagnosis. This is mainly attributed to the high proportion of OST patients who 
engaged in treatment over a long period. 
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Over the past four years, an increase can be seen in the reported number of patients 
entering treatment with cannabis as their main problem drug. The admission of patients 
diagnosed with PDU related to several drugs, cocaine, other stimulants and 
sedatives/hypnotics is fairly stable, although there has been an observed decrease in 
problem opioid users entering treatment within the last two years. However, the treatment 
data collection system was revised in 2010 with limitations in comparability with EMCDDA 
standards, e.g. only data on all treatment is collected with no distinction between types of 
treatment centre. 
Opioid substitution treatment 
There was a ‘rapid’ increase in the number of patients in OST from 2003 to 2014 (Selin et 
al., 2015), with approximately 500 additional patients engaged per year on average (Figure 
A.5.1). At the end of 2014, there were a total of 7 433 patients in OST, an increase from 373 
patients in 2013 (Waal et al., 2015). The number of prisoners receiving OST has also 
increased rapidly, from 766 patients a year in 2011 to 922 in 2012 (Selin et al., 2015). In 
2011, it was estimated by the EMCDDA that around three quarters (70 %; 95 % CI 54-
101 %) of all opioid users in Norway were engaged in OST, the highest coverage rate of any 
European country included in the analysis (11). A study by Selin and colleagues (2015) 
estimated OST coverage in Norway to be 74 %, although this was based on applying 2008 
prevalence data to 2012 treatment data. 
Figure A.5.1: Trends in the number of clients in OST, 2003-2014 (source: National Focal point report to the 
EMCDDA through Standard Table 24) 
 
Based partly on registry data, it is estimated that the proportion treated with methadone was 
39-40 % in 2014, while 57-58 % were treated with buprenorphine-based medication. Only 
2 % were treated with slow-release morphine. The proportion treated with methadone has 
been steadily declining in recent years. This is related to Norwegian guidelines for OST 
which do not recommend methadone as the first choice. 
The number of patients discharged from OST in 2014 was 681, somewhat lower than in 
2013 (711). This equates to 9.1 % of all patients being discharged from treatment in 2014, 
compared with 9.2 % in 2012’Viewed over a longer time series, 9 out of 10 patients appear to 
have been engaged in treatment for a relatively long time. 
(11) http://www.emcdda.europa.eu/stats13/hsrfig1a  
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Injecting equipment provision 
Based on a survey conducted in 2012, it was estimated that more than three million syringes 
were distributed that year, just over half of them in Oslo, equivalent to over 300 syringes per 
individual who injects drugs (EMCDDA, 2015) (12). 
Injection room 
In 2009, the Storting decided to make the provisional Act relating to drug injection rooms (13) 
permanent, which means that municipalities that wish to establish injection rooms have a 
legal basis for doing so. So far, however, only Oslo has made use of the Act. 
The number of registered users at the Oslo injection room has increased markedly since its 
opening as a trial scheme in 2005, from 400 in 2006 to nearly 3 000 in 2014. In addition to 
an increase in registrations, the number of injections taking place in the facility per year has 
increased over the same period, from 8 101 in 2006 to 35 392 in 2014. Based on 
communication with the local focal point, indications suggest that the injection room is now 
more likely to be used by stimulant users than opioid users, largely because of the decrease 
in heroin use among PWID. 
Take-home naloxone 
During the spring of 2014, a project was established for a take-home nasal naloxone 
programme. Since it started, almost 200 staff members have been trained to be instructors. 
By December 2015, an estimated 2 050 naloxone sprays had been distributed, and 67 
reports of returns for refills were registered between June 2014 and September 2015. The 
latter number includes returns for any reason, whether the spray was used for an overdose, 
lost or stolen. 
Drug-induced deaths: overall 
Figure A5.2: Crude number of annual drug-induced deaths recorded in Norway, 2004-2013 (source: National 
Focal point report to the EMCDDA through Standard Table 6) 
 
In Norway, the annual number of DIDs fell from 303 in 2004 to 234 in 2013, a decrease of 
23 % (Figure A5.2). By era, DIDs averaged 265 per annum between 2004 and 2008, 
decreasing to 255 per annum in the most recent five-year period for which data are available 
(12) This figure does not include syringes sold through pharmacies. 
(13) Proposition No 59 to the Odelsting (2008-2009) concerning the Act amending provisional Act No 64 of 2 July 2004 relating 
to a Trial Scheme of Drug Injection Rooms (the Act relating to injection rooms), etc. 
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(2009-2013). A visual inspection of the data suggests that the overall numbers of DIDs have 
been decreasing since 2009 and are at their lowest level since 2005. 
The overall proportion of DIDs in Norway accounted for by males has remained relatively 
stable, at between 73 % and 80 % across the time series. The average (mean) age of those 
affected has increased over the time series, from 37.5 years between 2004 and 2008 to 41.0 
years between 2009 and 2013. 
Between-era differences in DIDs across different age groups also show evidence of change, 
with a significant decline in the proportion of cases involving those aged under 25 years 
(2004-2008: 14 %; 2009-2013: 10 %; p < 0.01) and a significant increase in the proportion of 
cases involving those aged over 45 years (2004-2008: 25 %; 2009-2013: 39 %; p < 0.01). 
Drug-induced deaths: toxicology 
The number of deaths with opioids recorded in toxicology fell from 260 in 2004 to 186 in 
2013, a decrease of 28 %. Opioid-related DIDs averaged 226 per annum between 2004 and 
2008, falling to 206 per annum in the most recent five-year period for which data are 
available (2009-2013). Indeed, when comparing the presence of opioids in DID toxicology 
between eras, the data show a significant drop between the 2004-2008 (85 %) and 2009-
2013 (81 %) periods (p = 0.03). A visual inspection of the data shows patterns similar to 
those for the overall number of DIDs; the overall numbers decreased sharply between 2009 
and 2010 and steadily thereafter (Figure A.5.2). Parallel patterns are perhaps to be expected 
given that opioid-related DIDs account for over 80 % of all DIDs in Norway. 
SMR data reveal that, in 2013, although 79 % of DIDs were related to opioids, only 29 % 
were related to heroin alone and 22 % were related to other opioids, such as 
morphine/codeine, 20 % to methadone and 8 % synthetic opioids. There has been a 
significant reduction in the involvement of heroin in Norwegian DIDs since 2009. Other 
opioids such as methadone have overtaken heroin as the main intoxicant, and the 
proportions of methadone-related deaths have increased in recent years. 
Summary 
The number of DIDs in Norway has been falling since 2009. The absence of robust long-
term prevalence data on PDU, in particular POU, limits the ability to draw any meaningful 
conclusions as regards the drivers of this increase, for example whether the increase in 
DIDs reflects an increase in the number of individuals using drugs or is due to an increased 
risk of DID among this population. However, decreases in the number of opioid-related DIDs 
and increases in clients engaged in OST could point towards a positive impact of treatment 
engagement on mortality. Indeed, available evidence suggests that OST coverage in 
Norway is high (> 70 %) and that heroin-related treatment presentations have been 
decreasing in recent years, which suggests that the majority of those available and 
motivated to engage have been accessed. Moreover, treatment retention is high, which is 
also likely to contribute to reducing mortality. 
For those unable to access treatment, needle/syringe exchange is established, an injection 
room is in operation in the largest city (Oslo) and THN is available nationwide. In addition to 
a decrease in the number of syringes distributed, local intelligence suggests that the 
injection room is more likely to be used by stimulant injectors than it was when it was first 
opened (at which time it was used predominantly by opioid users), thus further contributing 
to an overall picture of decreasing heroin injecting in Norway. The THN programme has 
been able to supply 9-20 times as many naloxone kits as there are opioid-related deaths, 
which, for Norway, is around 1 500-2 000 based on the lower estimate. Both of these 
interventions are also likely to be contributing to maintaining the decline in drug-related 
mortality rates experienced in Norway since 2009. 
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Appendix 6: Scotland 
Sources of data on overdose 
DRD data for Scotland are compiled annually by the National Records of Scotland (NRS). 
The NRS holds details of all deaths registered in Scotland. The relevant questionnaire was 
revised for 2008, in order to collect more complete information about the substances present 
in the body; therefore, the figures for 2007 and earlier are not directly comparable with the 
figures for 2008 onwards on the new standard basis. 
 
For purposes of comparison with other European countries in this project, the NRS have 
provided a DRD dataset which complies with the EMCDDA criteria for its GMR. Scotland 
also hosts a National Drug-Related Death Database (NDRDD), which is coordinated, 
analysed and published by the ISD. The NDRDD effectively contains a subset of the NRS 
figures, but collects a much larger dataset covering characteristics of the deceased and their 
individual risk factors and behaviours. 
Background epidemiology 
Estimates of ‘problem drug users’ 
Using CRC methodology, the estimated number of individuals with problem drug use (14) in 
Scotland in 2012/2013, aged 15 to 64 years, is 61 500 (95 % CI 59 900-63 300) (ISD, 2014). 
The equivalent estimate for 2009/2010 is 59 600 (95 % CI 58 300-61 000). Although 
injecting prevalence was not reported in the 2014 publication, an estimate was provided in a 
previous prevalence report based on 2006 data (Hay et al., 2009). In 2006, 24 000 people 
are estimated to have injected opioids and/or benzodiazepines. Overstall et al. (2014) 
reported a somewhat lower figure (15 000) for 2009 using log-linear modelling methodology. 
Drug-related infectious diseases 
The prevalence of HCV among PWID has been stable for the past few years, changing from 
53 % to 58 % between 2008 and 2016 (PHE et al., 2016). The number of new cases of HIV 
among PWID remained relatively stable between 2005 and 2014, until a significant spike in 
2015 associated with an outbreak in the Glasgow City area increased prevalence rates to 
almost 2 %. 
Drug treatment data 
The Scottish Drug Misuse Database (SDMD) was set up in 1990 to collect information about 
people with PDU, based on data obtained when individuals first made contact with services 
providing tier-3 and -4 interventions (i.e. structured community and residential treatment) or 
reinitiated contact following a gap of at least six months since last attendance. Services 
contributing to the SDMD include specialist drug services and some medical services. 
 
In 2014/2015, among the 8 692 individuals providing information on recent ‘illicit’ drug use 
(including novel psychoactive substances/legal highs), heroin (3 955; 46 %) was the drug for 
which people most commonly sought treatment, followed by cannabis (1 762; 20 %) and 
diazepam (868; 10 %). The percentage of individuals reporting heroin as their main drug has 
decreased from 64 % in 2006/2007. The percentage of people under 25 years reporting 
recent heroin use decreased from 58 % (1 592/2 729) in 2006/2007 to 23 % (362/1 547) in 
2014/2015. A general downwards trend in the percentage of individuals reporting current 
injecting since 2006/2007 (28 %) was also observed. 
(14) Problem use of opioids and/or benzodiazepines. It is not possible to define how many individuals used opioids, benzodiazepines or 
both.  
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Opioid substitution treatment 
In 2014/2015, for the fourth successive year, there was a decrease in the dispensing of OST 
drugs (including methadone). However, the proportion of OST prescriptions that were 
accounted for by Suboxone has increased year on year from 1% 2007/2008 to 14% in 
2015/2016. 
 
The declining number of items dispensed as an OST (including methadone hydrochloride) 
does not necessarily represent a decline in the number of individuals receiving OST. Indeed, 
this may represent a change in practice (e.g. an increase in take-home prescriptions for 
OST), a change in the demographic presenting to treatment service (e.g. fewer new opioid 
users who require more intensive one-to-one appointments when commencing OST) or a 
change in policy (e.g. a greater focus on abstinence-based recovery, which therefore affects 
treatment demand and discharge strategies). 
 
The number of individuals prescribed specific drugs can be estimated using the Community 
Health Index (CHI) numbers captured on prescriptions. Because of sub-optimal CHI capture 
rates, the estimates below should be regarded as a minimum count of individuals prescribed 
methadone hydrochloride 1 mg/ml solution within Scotland. In 2014/2015, methadone 
1 mg/ml solution was prescribed at least once to 25 170 individuals (based on prescriptions 
with a valid CHI).The number of individuals prescribed methadone 1 mg/ml solution appears 
to have reduced from 26 202 individuals in 2011/2012; however, this change should be 
treated with caution in light of the abovementioned caveats. 
 
Based on available prevalence estimates, crude estimates suggest that a minimum of 
around 40 % of PDUs in Scotland are engaged in OST, a rate which appears to have 
remained relatively unchanged in recent years. 
 
Injecting equipment provision 
In 2014/2015, 328 329 attendances were reported by IEP outlets, an increase from 226 056 
in 2013/2014. Approximately 4.4 million needles and syringes were reported to have been 
distributed by participating outlets in 2014/2015, an increase from 2013/2014 (3.8 million). 
Nationally, it was estimated that an average of 71 needles and syringes were distributed per 
problem drug user in 2014/2015. The number of outlets distributing injecting paraphernalia 
has increased over time, from just over 250 in 2009/2010 to almost 300 in 2014/2015. 
Naloxone 
A national THN programme was launched in 2011 following successful pilots in three local 
areas. In total, 29 185 THN kits were issued by the national naloxone programme from 1 
April 2011 to 31 March 2016. Because of carry-over of THN kits from previous years, the 
availability of naloxone in Scotland is likely to have exceeded 20 times the number of opioid-
related deaths (i.e. 8 000 per annum) in 2013/2014, 2014/2015 and 2015/2016. Scotland’s 
national naloxone programme has been associated with a 36 % reduction in the proportion 
of opioid-related deaths in the four weeks following prison release, its primary outcome 
indicator (Bird et al., 2016). 
Drug-induced deaths: overall 
In Scotland, the number of annual DIDs increased from 415 in 2006 to 637 in 2015, an 
increase of 53 % (Figure A.6.1). Since 2000, the number of DIDs has increased by 99 %. By 
era, DIDs averaged 488 per annum between 2005 and 2009, rising to 567 per annum in the 
most recent five-year period for which data are available (2011-2016). A visual inspection of 
the data suggests that the overall number of DIDs increased steadily until 2008, fluctuated 
over the following five years, before increasing again in the last five years. The overall trend 
is upwards and the most recent year for which data are available represented the highest 
ever annual total of DIDs recorded in Scotland. 
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Figure A.6.1: Crude numbers of annual drug-induced deaths recorded in Scotland, 2000-2015 
(source: National Records of Scotland, 2016) 
 
 
The proportion of DIDs in Scotland accounted for by males has decreased from a peak of 
86 % in 2006 to 70 % in 2015, the lowest level recorded across the time series. Female 
DIDs, in contrast, appear have steadily increased over time. Between-era differences in 
DIDs across different age groups suggest that the proportion of cases in the younger age 
groups is decreasing and the proportion of cases in older age groups is increasing; in 
particular the average numbers of DIDs among those aged 45-54 (from 64 to 124), 55-64 
(from 19 to 38) and 65 years and over (from 7 to 15) doubled between 2006 and 2015. In 
comparison, the average number DIDs in those aged 15 to 24 years almost halved between 
the 2006-2010 (mean = 76) and 2011-2015 (mean = 40) periods. 
Drug-induced deaths: toxicology 
The number of cases recorded involving only opioids decreased from 79 in 2008 to 32 in 
2015, a decrease of 59 %. Opioid-only DIDs averaged 64 per annum between 2008 and 
2011, falling to 42 per annum in the most recent four-year period for which data are available 
(2012-2015). Polydrug deaths involving opioids, however, increased from 439 to 550, an 
increase of 25 % (Figure A6.1). Looking more closely at specific substances, the recent 
spike in opioid-related deaths appears to have been driven by heroin/morphine involvement, 
which has notably increased for the first time since it slumped between 2008 and 2011 
(Figure A.6.2). The number of deaths involving methadone appears to have levelled off, after 
a peak in 2011. Of the other substances recorded, particularly notable trends include the 
decreasing involvement of alcohol across the time series, the volatile year-to-year trend in 
benzodiazepine involvement and a spike in cocaine-related cases in 2015. The number of 
deaths involving new psychoactive substances is relatively low and such deaths are likely to 
also involve other substances. 
 
Figure A.6.2: Crude numbers of annual opioid-related drug-induced deaths recorded in Scotland, by 
drug, 2008-2015 (source: National Records of Scotland, 2016) 
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 Purity 
At UK level, after low levels were recorded during both 2011 and 2012, heroin purity has 
increased over the last two years and is now higher than in 2010 (UK Focal Point on Drugs, 
2015). The street-level price per gram has also increased. However, the purity-adjusted 
price has fallen considerably from a peak of around GBP 74 per gram in 2011 to around 
GBP 45 in 2014 as a result of an increase in the quality of the substance typically being sold 
at street level. 
Summary 
DIDs in Scotland are at historically high levels despite the availability of OST, the 
widespread provision of injecting equipment and a world-leading national THN programme. 
Although prevalence has been fairly stable in recent years, the existing cohorts have 
become older and therefore more at risk of death. This ‘ageing cohort’ is evident from all 
data sources on drug use in Scotland, including mortality, morbidity and treatment statistics. 
The number of problem drug users within this ageing cohort is increasing every year, 
creating an ageing epidemic with regard to drug-related mortality, which is seen elsewhere in 
Europe but appears particularly acute in Scotland, a country for which evidence has 
demonstrated the population to be vulnerable to excessive death rates that are not 
explained by deprivation (‘the Scottish effect’); these deaths are typically caused by violence, 
suicide, or alcohol and drug use (McCartney et al., 2015). A further demographic feature of 
the Scottish data is the substantial increase in DDs among females relative to males, with 
over a 100 % increase observed in the past 10 years. The ageing effect is more pronounced 
in females than in males and may account for this trend; however, there may be other 
contributing factors that have yet to be identified. 
 
OST coverage has remained relatively constant in recent years, at around 40 %. It is not 
clear, however, which 40 % of the PDU population is engaged (i.e. whether or not it is those 
most at risk of DRD) and to what extent those in treatment are ‘stable’ or whether or not they 
are dropping in and out regularly and thus are at elevated risk of overdose and death. 
Recent evidence from Gao et al. (2016) suggests that methadone-specific death rates are 
higher in older age groups (35 years and over) than in younger clients; in the context of 
Scotland’s ageing population, this may have contributed to the increase in methadone-
related deaths between 2010 and 2011. 
 
Scotland’s naloxone programme has been associated with a decrease in opioid-related 
death rates among prisoners after release. However, the overall opioid-related death rate 
remains high and increased sharply in 2015 with heroin involvement at its highest levels 
since 2008. This may be an indication that the legacy of the heroin drought is now over in 
Scotland, a theory that is supported by purity levels, which have been rising again in recent 
years. In parallel with the resurgence in heroin purity recorded in drug seizure statistics, the 
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data demonstrate a steep rise in heroin-related polydrug deaths (typically alongside 
benzodiazepines and alcohol). 
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Appendix 7: Sweden 
Sources of data on overdose 
Data are sourced from the Cause of Death Register (CDR). It is estimated that 99 % of all 
deaths occurring in Sweden are included in the CDR (Stenbacka et al., 2010). In addition to 
the CDR, there is an SMR called ‘Toxreg’, comprising all deaths where illicit drugs are found 
at forensic toxicological examination; virtually all forensic examinations include toxicological 
examination (approximately 5 000 per year). 
Background epidemiology 
Estimates of ‘problem drug users’ 
The latest estimate of PDU, based on data from 2007, was published in 2010 (Statens 
Folkhälsoinstitut, 2011) and suggests that there are almost 30 000 individuals with 
‘problematic use of drugs’ in Sweden. This figure includes users of opioids and other drugs 
but with no breakdown as regards the size of each drug sub-group. In addition, it is 
estimated that there were around 8 000 PWID in Sweden in 2011 (NBHW, 2013). 
Drug-related infectious diseases 
In various studies conducted during the last 15 years, HCV prevalence among PWID in 
Sweden has been reported to be between 60 % and 80 %. HIV prevalence among PWID 
continues to remain at very low levels, with only four domestic cases being reported in 2014 
and two in 2013. Among PWID, 38 cases of HBV infection were reported in 2014. 
 
In 2014, a review of the historical data reported by Sweden to the EMCDDA in Tables 1-4 of 
Standard Table9 (infectious diseases) and Standard Table 10 (syringe availability) 
concluded that these data could not provide a representative picture of the national situation 
for PWID in Sweden, nor did they allow any comparison between the years; therefore, any 
interpretation of the data must be undertaken with caution. 
Drug treatment data 
Swedish TDI data are created through the collection of data from three separate information 
systems: (1) the national patient registry (outpatient and inpatient treatment services); (2) 
DOK (homes providing compulsory care for adult substance users); and (3) Prison and 
Probation Services. The last two sources function on a voluntary basis. It is not possible 
within the current data collection system to determine whether or not a person is counted 
several times across different data sources. Moreover, the Swedish TDI system is still under 
development in relation to many aspects of harmonisation with EMCDDA standards. 
 
Opioids were the most common drug reported among treatment entrants in Sweden in 2014, 
with cannabis and hypnotics/sedatives the second most prevalent. Overall, the primary drug 
distribution is similar when comparing inpatient and outpatient clients. The number of clients 
receiving inpatient and outpatient care has increased during the last five years. In 
compulsory care, increases in opioid and stimulant drugs as the primary drug have been 
reported over the same period, as have increased in the proportion of clients who use 
several different substances each day. 
Opioid substitution treatment 
In 2014, 3 502 individuals were registered as OST clients, 96 of which received treatment in 
prison. Of these, 2 071 received buprenorphine and 1 520 received methadone, although 
there is the potential for double counting in the data. From 2006 to 2011, the number of 
clients in OST continuously increased, followed by a slight decline thereafter linked to a fall 
in the number of clients receiving methadone (Figure A.7.1). 
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Figure A.7.1: Trends in the numbers of clients in OST, 2003-2012 (source: National Focal point report 
to the EMCDDA through Standard Table 24) 
 
Injecting equipment provision 
In total, 2 266 active clients were reported across the six needle exchange programmes 
(NEPs) in Sweden in 2014. The largest NEP, in Stockholm, has been running for 
approximately 1.5 years and had about 1 400 active clients during 2014, 77 % of whom were 
male. 
Take-home naloxone 
A pilot THN project was scheduled to start in Skåne county by late 2015. 
Drug-induced deaths: overall 
Figure A.7.2: Crude number of annual drug-induced deaths recorded in Sweden, 2005-2014 (source: 
National Focal point report to the EMCDDA through Standard Table 6) 
 
 
In Sweden, the annual number of DIDs increased from 204 in 2005 to 609 in 2014, an 
increase of almost 200 % (Figure A.7.3). By era, DIDs averaged 253 per annum between 
2005 and 2009, increasing to 433 per annum in the most recent five-year period for which 
data are available (2010-2014). A visual inspection of the data suggests that the overall 
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number of DIDs has increased consistently across the time series, with sharper annual 
increases evident in the past five years. 
 
The overall proportion of DIDs in Sweden accounted for by males has remained relatively 
stable, at between 72 % and 78 % across the time series. The average (mean) age of those 
affected has also remained stable over the time series, at 40.2 years between 2005 and 
2009 and 39.9 years between 2010 and 2014. Between-era differences in DIDs across 
different age groups show some change, with significant increases in the proportion of cases 
involving those aged under 25 years (2005-2009: 21 %; 2010-2014: 33 %; p < 0.01) and 
those aged over 55 years (2005-2009: 11 %; 2010-2014: 17 %; p < 0.01). 
 
Drug-induced deaths: toxicology 
The number of deaths with opioids recorded in toxicology increased from 130 in 2005 to 507 
in 2014, an increase of almost 300 % (Figure A.7.2). Opioid-related DIDs averaged 198 per 
annum between 2005 and 2009, rising to 370 per annum in the most recent five-year period 
for which data are available (2010-2014). When comparing the presence of opioids in DID 
toxicology between eras, a significant increase between the 2005-2009 (83 %) and 2010-
2014 (88 %) periods (p < 0.01) is apparent. A visual inspection of the data shows patterns 
similar to those for the overall number of DIDs; the overall numbers increased consistently 
across the time series, with steep rises in the past five years. Parallel patterns are perhaps 
to be expected given that opioid-related DIDs account for over 80 % of all DIDs in Sweden. 
 
The data available in the SMR show that the number of cases in which methadone and 
buprenorphine were present in the blood at the time of death has increased from 2010 
onwards, and (when combined) account for higher numbers of DRDs than heroin/morphine. 
Other 
A recent study investigated the reasons for the almost doubling of DRDs in Sweden in the 
past 10 years (Leifman, 2016). The research suggests that a real increase in DRDs has 
occurred, but that the scale of the increasing trends previously reported has been greatly 
exaggerated. The main reason for this exaggeration is that the changes — or improvements 
— in methods of analyses (recording practices) within forensic investigations (more cases 
tested and lower threshold for drug detection) have led to the detection of more deaths with 
positive findings of drugs. As reported by the National Board of Health and Welfare (NBHW, 
2016), changes in coding practices related to dextropropoxphene have also contributed to a 
false rate of increase. 
 
The increase that remains after controlling for changes in recording practices is still 
substantial and is due to an increase in the number of opioid-related deaths (from 2008 to 
2014, with an approximately 33 % increase in absolute numbers and a 27 % increase per 
inhabitant aged 15 or over). Interestingly, the increase in DRDs is observed among both 
men and women and across several age groups. It appears that there has been a more or 
less collective shift upwards in DRDs, so that the gender and age distributions look much the 
same today as they did 10 to15 years ago. Polydrug use is a key factor in this increase, 
particularly the combined use of benzodiazepines and opioids. 
 
Analyses of the manner of death in poisoning cases show clearly that it is the number coded 
as unintentional poisoning deaths that has increased over the past 10 years or so, whereas 
both intentional (suicides) and undetermined poisoning deaths have remained rather stable. 
This may suggest that the increase is mainly due to overdoses among drug addicts. 
 
The report concludes by stating that ‘the inconsistencies in the Swedish data on drug-related 
deaths also question the comparability of the Swedish statistics with other European 
countries, both in levels for specific years and in country-specific trends’. 
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Summary 
The number of DIDs recorded in Sweden increased markedly between 2005 and 2014. In-
depth analysis suggests that the scale of the increase is largely as a result of methodological 
improvements in data collection. Despite this, an increasing trend in DRDs is still observed 
over the time series after controlling for overestimation, but not to the extent that the data 
reported to EMCDDA ST6 would suggest. This increase is strongly associated with a rise in 
the number of opioid-related deaths among both men and women and across several age 
groups, with polydrug use a key factor. The increase in DIDs also appears to be principally 
driven by deaths as a result of accidental overdose. 
The absence of robust prevalence data on POU limits the ability to draw any meaningful 
conclusions on the drivers of this increase, for example whether the increase in DIDs reflects 
an increase in the number of individuals using drugs or is due to an increased risk of DID 
among this population. However, increases in the number of opioid-related DIDs and in 
clients engaged in OST could point towards an overall increase in prevalence. 
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